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ABSTRACT 
 
Heinzman, Christina MSN, DNP, Wright State University-Miami Valley College of 
Nursing and Health/University of Toledo, 2018. The Role of Antibiotic Therapy in the 
Treatment of Small Bowel Bacterial Overgrowth in the Pediatric Population with Short 
Bowel Syndrome.  
 
 
Short bowel syndrome is the congenital or surgical alteration of the small bowel resulting 
in a shorter than normal length of small bowel.  This condition affects approximately 
20,000 people in the Unites States and is diagnosed in 3-5 times per 100,000 live births 
annually.  Patients with short bowel syndrome are at risk for the development of small 
bowel bacterial overgrowth, a serious consequence caused by overgrowth of bacteria in 
the small bowel resulting in symptoms of abdominal pain, abdominal distention, feeding 
intolerance, malabsorption, weight loss and increased risk of metabolic acidosis.  Clinical 
studies assessing the role of antibiotic therapy in the pediatric population are nearly non-
existent forcing clinicians to rely on adult literature for guidance.  Diagnostic testing 
methods are often invasive and difficult to perform in pediatric patients leaving clinicians 
to diagnosis this condition based on symptomology.  Treatment is often prescribed based 
on clinical experience and published expert opinion.  Inconsistency in the diagnosis and 
medical treatment of small bowel bacteria overgrowth is problematic and warrants further 
investigation.  The purpose of the evidence-based project was to establish the role of 
antibiotic therapy in the treatment of small bowel bacterial overgrowth in pediatric 
patients with short bowel syndrome.  A one-year retrospective chart review of pediatric 
	
	 iv 
patients admitted to the Gastroenterology/Lumen service at Cincinnati Children’s 
Hospital Medical Center between 5/1/2016-5/1/2017 was conducted.  Final analysis of 
the data revealed inconsistency in antibiotic prescribing, however, the effectiveness of 
treatment was inconclusive due to lack of provider documentation.  As a result of the 
findings, a best evidence statement (BESt) has been drafted for publication throughout 
the institution with the intent to standardize antibiotic prescribing practices for this 
population.  Developing initiatives that stemmed from this evidence-based practice 
project include improved diagnosis by means of DNA mapping, revisions to nursing 
standards for central line care in patients with an ostomy, and a poster presentation at a 
national conference.  
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I.  PROBLEM STATEMENT 
Pediatric patients with short bowel syndrome are at increased risk for the 
development of small bowel bacterial overgrowth (SBBO), a serious consequence 
characterized by an overgrowth of bacteria within the lumen of the small bowel.  
Literature regarding the role of antibiotic therapy to treat SBBO in pediatric patients is 
limited and mostly consists of expert opinion and case reports.  Due to the lack of clinical 
research and standard guidelines for treatment of SBBO in pediatric patients with short 
bowel syndrome, care provided within the Division of Gastroenterology, Hepatology, and 
Nutrition at Cincinnati Children’s Hospital Medical Center (CCHMC) is variable.  The 
inconsistency in clinical care and opinions regarding the role of antibiotics to treat small 
bowel bacterial overgrowth is problematic.  Some providers recommend prophylactic 
antibiotics for all patients with short bowel syndrome while some recommend them only 
in certain situations.  Some providers never recommend prophylactic antibiotics under 
any circumstance.  Findings from the literature suggest the use of antibiotics in 
symptomatic patients (Ching, Gura, Modi, & Jaksic, 2007; Cole & Kocoshis, 2013; Cole 
& Ziegler, 2007; Dehmer, Fuller, & Helmrath, 2011; DiBaise, Young, & Vanderhoof, 
2006; Malik, Xie, Wine, & Huynh, 2011; Quigley & Quera, 2006; Reed, 2014; Sentongo, 
2008; Shah, Day, Somsouk, & Sewell, 2013; Sieczkowska, Landowski, Kaminska, & 
Lifschitz, 2016; Vanderhoof, Young, Murray, & Kaufman, 1998; Vanderhoof, Young, & 
Thompson, 2003; Youssef, Mezoff, Carter, & Cole, 2012), however experts in the field 
are recently moving away from prophylactic use of antibiotics because the risk of 
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repeated antibiotic exposure may outweigh the benefits.  An evidence-based project was 
undertaken to determine the role of antibiotic therapy in the treatment of small bowel 
bacterial overgrowth in pediatric patients with short bowel syndrome.  
Background 
Description of short bowel syndrome 
Short bowel syndrome (SBS) is the congenital or surgical alteration of the small 
bowel resulting in a shorter than normal length of small bowel.  This condition presents 
in 3-5 per 100,000 live births per year and there are approximately 20,000 children and 
adults currently living in the United States with short bowel syndrome (Cole, Hansen, 
Higgins, Ziegler, & Stoll, 2008; Squires et al., 2012).  Although this condition can also 
occur in adults, this project only focused on the pediatric population.  
Short bowel syndrome can occur naturally as a result of a congenital anatomic 
anomaly or as a consequence of a surgical procedure.  Congenital forms of short bowel 
syndrome are caused by deviations in the fetal development of the gastrointestinal tract 
such as omphalocele, gastroschisis, or intestinal atresias.  Surgical resections of the bowel 
may be performed to treat necrotizing enterocolitis, ischemic bowel from malrotation or 
volvulus, or stenotic bowel from inflammatory bowel disease (Bhatia & Mundy, 2013).  
Those with altered lengths of bowel may suffer from many complications including 
intestinal failure with related nutritional deficiencies and malabsorption, altered motility, 
abdominal distention, reflux, vomiting, poor growth, dehydration, metabolic acidosis, 
accumulation of D-lactate leading to D-lactic acidosis, septic bacteremia, and risk for 
overgrowth of bacteria in the small bowel which can escalate the significance of each of 
the preceding complications (Xie, 2011).  
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Classification of short bowel syndrome 
 The average length of small bowel for an infant is 250-300 cm compared to 700 
cm for the typical adult.  The average length of bowel for someone diagnosed with short 
bowel syndrome depends on their congenital anomaly or past surgical procedures.  Short 
bowel syndrome encompasses people who have half or more of their small bowel 
resected.  Ultra-short bowel syndrome refers to those who have less than 25% of small 
bowel remaining.  
Definition of small bowel bacterial overgrowth 
There is no consensus regarding the definition of small bowel bacterial 
overgrowth (Sieczkowska et al., 2016).  However, the definition most frequently used 
describes SBBO as the presence of >100,000 colony-forming units of bacteria/mL of 
luminal aspirate within the proximal bowel (Cole & Ziegler, 2007).  The definition has 
limited clinical value, as symptoms of SBBO depend on the microbiological composition 
of the contaminating microbiota (Sieczkowska et al., 2016).  For example, a large number 
of gram-positive bacteria from the upper respiratory tract will not have the same clinical 
effect as the same number of colonic bacteria growing in the small bowel.  This suggests 
that a more appropriate definition of SBBO is the presence of >100,000 colonic-type 
bacteria grown from a small bowel aspirate (Sieczkowska et al., 2016).  
Prevalence of Small Bowel Bacterial Overgrowth 
Due to difficulty in performing diagnostic testing in this population, information 
regarding prevalence of SBBO is limited.  DiBaise et al. (2006) report that little is 
actually known about the prevalence; however, in their clinical experience SBBO is 
commonly seen.  Similar to the DiBaise et al. (2006) study, the Pediatric Intestinal 
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Failure Consortium conducted a multi-center retrospective cohort study in 2012 and 
found that 76% of the 272 patients reviewed were given oral antibiotics for presumed 
overgrowth.  Confirmation diagnostic testing was not addressed in their report (Squires et 
al., 2012).  
There are currently more than 200 patients under the care of the Intestinal Care 
Center within the Division of Gastroenterology, Hepatology, and Nutrition at Cincinnati 
Children’s Hospital Medical Center.  Prevalence of small bowel bacterial overgrowth in 
this cohort is not well documented.  SBBO has an assigned ICD-10 code, but prevalence 
in this group has been difficult to track.  This difficulty is related to the often subjective 
diagnosis.  SBBO is often not listed as a coded diagnosis in the electronic medical record 
because generally only the chief symptoms are captured on the patient’s problem list.  
Risk factors for Small Bowel Bacterial Overgrowth 
Any process that disrupts or alters the microbiota homeostasis of the small bowel 
may lead to the development of SBBO (Scarpignato & Gatta, 2013).  The microbiota, 
commonly known as gut flora, is the complex community of organisms that live in the 
digestive tract.  DiBaise et al. (2006) and Bohm et al. (2013) catalog the conditions that 
are associated with the development of SBBO into three categories including anatomic, 
functional, or multi-factorial. 
Anatomic conditions that are associated with the development of SBBO include 
congenital and acquired abnormalities.  Congenital abnormalities include jejuno-ileal 
webs, small bowel atresias, gastroschisis, and omphalocele.  Acquired abnormalities 
include perinatal obstructive conditions as seen in necrotizing enterocolitis, midgut 
volvulus, and ischemia.  Other acquired anatomic conditions include enterocutaneous 
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fistula, duodenal or jejunal diverticulosis, surgically created blind loops, presence of an 
ostomy, intestinal strictures, and resection of the ileocecal valve (Cole & Ziegler, 2007; 
DiBaise et al., 2006; Malik et al., 2011; Sentongo, 2008).  The ileocecal valve is a 
muscular sphincter that separates the small intestine and the large intestine.  The main 
function of the ileocecal valve is to prevent the backwash of colonic bacteria into the 
small intestine.  Failure of this process due to surgical resection of the ileocecal valve 
increases the risk for bacterial contamination into the small bowel and increases the 
potential for bacterial overgrowth.  
Intestinal dysmotility caused by strictures, adhesions, mucosal inflammation or 
exposure of the small bowel to amniotic fluid as seen in gastroschisis are functional risk 
factors for bacterial overgrowth (Cole & Ziegler, 2007; DiBaise et al., 2006; Malik et al., 
2011; Scarpignato & Gatta, 2013; Sentongo, 2008).  Reflux of bacteria from the colon 
into the small intestine combined with poor motility, bowel dilation, and stasis of the 
small bowel promote bacterial overgrowth (Ching, Gura, Modi & Jaksic, 2007).  Failure 
of small bowel clearance due to primary visceral neuropathies or myopathies such as 
chronic intestinal pseudo-obstruction (CIPO), megacystis microcolon intestinal 
hypoperistalsis syndrome (MMIHS), or radiation enteropathy decrease the phase III 
contractions of the migrating motor complex (MMC).  The MMC works to sweep the 
small bowel every 90-120 minutes to clear it of debris and remnant food.  Failure of this 
system can lead to stasis and overgrowth of bacteria (Bohm et al., 2013).  
Other functional risk factors include the loss of protective gastric barrier as found 
in Helicobacter pylori, proton pump inhibitor use, hypochlorhydria, and total or subtotal 
gastrectomy (Bohm, Siwiec, & Wo, 2013a; Cole & Ziegler, 2007; DiBaise et al., 2006; 
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Scarpignato & Gatta, 2013).  In an otherwise normal physiologic gastric pH environment, 
99% of all bacteria in the stomach would be eliminated within 5 minutes (Bohm et al., 
2013).  In the absence of gastric acid as found with proton pump inhibitor use, the same 
bacterial species can be found in the stomach and in the proximal small intestine (Bohm 
et al., 2013).  
Immunodeficiency, malnutrition, chronic pancreatitis, and parenteral nutrition 
dependency make up the multi-factorial category (DiBaise et al., 2006).  Gutierrez et al. 
(2012) conducted a retrospective chart review of 57 pediatric patients who underwent 
endoscopic evaluation for SBBO and found a strong and independent association 
between parenteral nutrition use and incidence of SBBO (p = 0.01).  The presence of 
SBBO was defined as the presence of >100,000 colony forming units of bacteria/mL of 
duodenal aspirate.  Given the surgical and medical treatments needed to sustain the life of 
a patient with short bowel syndrome, many patients fall into one or more of these risk 
categories. 
Signs and symptoms of small bowel bacterial overgrowth 
Signs and symptoms of SBBO have been described as vomiting or feeding 
intolerance, abdominal pain, abdominal distention and bloating, increased flatulence, 
diarrhea, steatorrhea, hematochezia, weight loss, malabsorption of fat and carbohydrates, 
and metabolic acidosis from the accumulation of D-lactate (Bohm, et al. 2013; Cole & 
Ziegler, 2007; Collins & Lin, 2011; de Boissieu, et al., 1996; DiBaise et al., 2006; Di 
Stefano et al., 2005; Malik et al., 2011; Reed, 2014).  Symptomology and severity of 
disease vary widely among individuals.  Regardless, each has the potential for negative 
health consequences.  
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Small Bowel Bacterial Overgrowth Clinical Consequences 
Bile acid deconjugation by luminal bacteria leads to fat malabsorption 
(Sieczkowska et al., 2016).  Fat malabsorption results in the formation of oxalate kidney 
stones, steatorrhea, and deficiencies in the fat soluble vitamins A, D, and E.  Although 
vitamin K is a fat soluble vitamin, deficiency is rarely seen due to the enteric flora’s 
natural production of vitamin K.  Deficiencies in vitamins A, D, and E can lead to vision 
loss, osteoporosis, and neurologic irritability respectively.  Deficient vitamins can be 
replaced orally, in enteral feeds, or by injection in parenteral nutrition.  It is common 
practice to replete vitamin deficiencies in pediatric patients when indicated.   
Carbohydrate malabsorption can result in D-lactic acidosis, a rare but serious 
neurologic condition that occurs in children with short bowel syndrome and SBBO.  
Malabsorbed carbohydrates move from the small intestine into the large intestine where 
they are fermented into the D-isomer form of lactic acid.  Humans cannot metabolize D-
lactic acid, so it is absorbed by the large intestine into circulatory system resulting in 
elevated serum levels of D-lactate.  As a result, patients develop D-lactic acidosis and 
exhibit symptoms of hyperventilation, altered mental status, confusion, cerebellar ataxia, 
slurred speech, and loss of memory (DiBaise et al., 2006, Sieczkowska et al., 2016).  
Serum D-lactic acid is not detected on routine L-lactic acid assays.  It is measured using 
specialized testing only available at designated reference laboratories.  Supportive 
biochemical findings for D-lactic acid are metabolic acidosis with increased anion gap 
and normal L-lactate concentration (Sentongo, 2008).  Impaired carbohydrate absorption 
also leads to the production of various gases that result in clinical symptoms of 
abdominal bloating, distention, and discomfort.  
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Protein malabsorption is not commonly seen in patients with SBBO, but a 
reversible form of protein-losing enteropathy has been reported (DiBaise et al., 2006).   
Protein losing enteropathy is characterized by the severe loss of serum proteins in the 
intestine.  In the case of SBBO, it is considered a reversible form of protein losing 
enteropathy and resolves as the SBBO resolves.  Protein malabsorption can be caused by 
the digestion of protein by bacteria or from mucosal damage and loss of absorptive 
surface of the small bowel (Sieczkowska et al., 2016).   
Increased gastrointestinal permeability associated with SBBO may promote 
translocation of enteric bacteria from the gastrointestinal tract into the mesenteric lymph 
nodes and visceral organs.  Enteric translocation elevates the risk of gut-derived sepsis 
(Sieczkowska et al., 2016). Cole et al. (2010) conducted a pilot study of ten infants with 
short bowel syndrome and dependence on parenteral nutrition.  They found a seven-fold 
increased risk of developing a central line associated-blood stream infection (CLA-BSI) 
in those who also had SBBO compared to those infants who did not.  
Anemia is another clinical consequence of SBBO caused by a combination of 
malnutrition, micronutrient malabsorption, competitive bacterial assimilation of nutrients, 
and increased losses due to SBBO-associated enteropathy (Sentongo, 2008).  Vitamin B12 
and folate deficiencies causing macrocytic anemia may result from competitive 
consumption of the vitamins by excessive bacterial growth (Sentongo, 2008; 
Sieczkowska et al., 2016).  Iron deficiency anemia can result from bacterial utilization of 
iron.  Onset of refractory normocytic anemia in patients with short bowel syndrome or 
SBBO should prompt suspicion of multiple micronutrient deficiencies including iron, 
vitamin B12, folate and copper (Sentongo, 2008).  
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Patients suffering from SBBO often complain of abdominal distention, abdominal 
pain, nausea, vomiting and intolerance of gastric feeds.  Complications of SBBO can 
delay or prevent the weaning of parenteral nutrition.  Prolonged use of parenteral 
nutrition increases the risk of intestinal failure-associated liver disease (IFALD).  It is 
estimated that 40-60% of children and up to 85% of neonates on prolonged parenteral 
nutrition will develop IFALD (Chan & Wu, 2014).  This type of liver disease combined 
with loss of central venous access sites due to repeated bacteremia make eventual listing 
for a liver transplantation a likely consequence (Xie, 2011).  
Quality of life for patients with chronic illnesses have additional stressors that 
affect not only the child but extend to their family and caregivers.  Stressors can include 
loss of time at work, disruption to family schedules and activities, limitations to travel, 
and increased responsibilities.  Often times these added stressors fall on the primary 
caregiving parent while the other maintains employment.  A review of literature 
regarding quality of life in children with chronic illness was conducted (Kourkoutas, 
Georgiadi, & Plexousakis, 2010).  By identifying quality of life specific situations for 
children, they can be better supported throughout their illness.  There are many 
instruments that measure quality of life in children with chronic illnesses and are often 
used to measure the influence that a certain disease has on the patient and family unit.  
When assessing the quality of life, it is important to collect data directly from both the 
patient and family when applicable as both are affected.  
Failure to recognize signs and symptoms of SBBO can result in delayed treatment 
leading to futile attempts to advance enteral feeds, prolonged use of parenteral nutrition 
with associated risks for IFALD, extended hospitalizations and increased healthcare 
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costs.  Spencer et al. (2008) reported a retrospective review of the total charges for 41 
patients with short bowel syndrome.  The study found that the majority of the $1,028,985 
- $1,619,751 spent in the first five years of life were spent during the first year of care 
alone and mostly due to hospitalization charges.  
Diagnosis of Small Bowel Bacterial Overgrowth 
Current diagnostic methods for SBBO include techniques that are invasive and 
not feasible in the pediatric population.  Diagnostic tests include direct aspirate culture of 
small bowel luminal contents, hydrogen breath testing, polymerase chain reaction-
denaturing gradient gel electrophoresis and small bowel biopsy.  Each method presents 
either a technical challenge, prohibitive cost, or the inability to properly assess with 
young children (DiBaise et al., 2006; Malik et al., 2011; Xie, 2011).  
Direct aspirate culture of small bowel fluid is considered to be the gold standard 
in the diagnosis of SBBO, but is often associated with significant limitations (DiBaise et 
al, 2006).  Aspirate cultures must be collected under general anesthesia during an 
esophagogastroduodenoscopy (EGD) procedure, which is not only a technical challenge 
and expensive but also places the pediatric patient at risk for potential scope related 
perforations and risks associated with anesthesia.  The aspirate only gives information for 
the area of the small bowel from which it was obtained.  This may not be reflective of the 
bacterial contents of the entire intestine leading to false negative results (Xie, 2011).  A 
standardized protocol does not exist for obtaining aspirates and there is lack of clarity for 
the cutoff values indicating a positive culture result.  For these reasons, this method is not 
an appropriate test for those with mild nonspecific symptoms or who need repeated 
testing (Sieczkowska, 2016).  
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Hydrogen breath testing is commonly used as an alternative method to diagnose 
SBBO, however it is difficult to administer (DiBaise et al, 2006).  This test is inaccurate 
when pediatric patients cannot breathe into the collecting device correctly and is 
ineffective for patients with respiratory distress (Malik et al., 2011).  This highly 
specialized testing requires specific equipment and trained technicians which are not 
readily available at many institutions (Xie, 2011).  Alternatives to the hydrogen breath 
test include the C and D xylose breath test, which measures pulmonary excretion of 
labeled CO2 produced from bacterial fermentation.  Although initial reports were 
promising, diagnostic specificity and sensitivity has not been confirmed (DiBaise et al., 
2006).  
Molecular fingerprinting of bacterial populations is a developing area of interest 
for clinical use, especially in the setting of intestinal failure and suspected SBBO.  
Deoxyribonucleic acid (DNA) fingerprinting techniques can be applied to non-invasively 
obtained specimens, such as fecal samples.  Using universal bacterial 16S ribosomal 
ribonucleic acid (RNA) primers, testing procedures produce a quantitative and qualitative 
result as well as specific detection of a wide range of bacterial species.  Polymerase chain 
reaction (PCR) is regarded as superior over standard culture because it can detect 
uncultivable or dead bacterial cells in situ; however DNA purification is required to 
decrease the interference of confounding factors such as the bile salts and bilirubin found 
in fecal samples making this testing method more complicated (Malik et al., 2011).  
Each of the above methods have varying utility for determining the presence of 
bacteria in the small bowel, but lack the ability to assess the consequences of the bacterial 
presence.  Small bowel biopsy specimens may provide the most useful information in 
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determining if the excess bacteria in the small bowel are causing harm.  Inflammation, 
villus blunting, and the presence of adherent or intracellular bacteria on biopsy are 
suggestive of SBBO (DiBaise et al., 2006).  However, obtaining a small bowel biopsy is 
also invasive and requires a sedated procedure, therefore not feasible for mild 
presentations or in very ill patients.  Due to the difficulty in testing for SBBO, diagnosis 
is often based on the clinicians’ assessment of the risk factors as well as clinical signs and 
symptoms. 
Purpose Statement 
 The main purpose for conducting the evidence-based practice project was to 
establish the role of antibiotic therapy as treatment for small bowel bacterial overgrowth 
in pediatric patients with short bowel syndrome using an evidence-based approach.  
There were two specific aims for this project.  The first aim was to increase provider 
knowledge about the risk factors for small bowel bacterial overgrowth, the signs and 
symptoms consistent with small bowel bacterial overgrowth, and the preferred antibiotic 
treatment options when clinically indicated.  The second aim was to develop a BESt 
document reflective of the recommendations derived from this project for institutional 
use.  
Evidence-based Practice Model 
Dramatic changes in healthcare and the continued growth of integrated healthcare 
delivery systems have increased the clinician’s desire to have up to date information on 
effective approaches to patient care (Rosswurm & Larrabee, 1999).  Clinicians can no 
longer rely exclusively on clinical experience, pathophysiologic rationale, and opinion-
based processes.  They must also must learn to search the literature, critically appraise 
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research findings, and then synthesize empirical and contextually relevant evidence.  The 
combination of critical thinking and evidence-based practice models for decision-making 
are essential for maximizing the quality and cost-effectiveness of patient care (Rosswurm 
& Larrabee, 1999).  
Evidence-based practice is known as the integration of the best available research 
combined with clinical expertise and patient values to promote clinical decision-making 
(Melynk, 2015; Rosswurm & Larrabee, 1999).  An increase in the number of clinical 
research studies, particularly randomized clinical trials, meta-analysis, and patient 
outcome studies has prompted the paradigm shift from traditional and intuition-driven 
practice to the new standard of evidence-based practice.  The use of evidence-based 
practice has been established to decrease the time between conducting research and the 
use of research in clinical settings. 
The process of implementing evidence-based practice into patient care can be 
overwhelming, complicated, and challenging.  These deterrents have led to the 
development of various evidence-based practice models.  The use of such models support  
an organized approach to implementation, improve the utility of available resources, and 
facilitate the evaluation of outcomes (Gawlinski & Rutledge, 2008; Schaffer, Sandau, & 
Diedrick, 2013).  The implementation of evidence-based practice takes into consideration 
patient preferences, availability of healthcare resources, high-quality research evidence 
and clinical expertise (Melynk, 2015). 
Originating in 1999, the process first named the Model for Change to Evidence-
Based Practice has since evolved and was updated in 2009.  It is now known as the 
Model for Evidence-Based Practice Change, rearranging the words to emphasize the type 
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of change that results from following the model (Larabee, 2009).  The Model for 
Evidence-Based Practice Change was used as a guiding framework for the project 
(Larabee, 2009).  The model is a six step process and is further described herein (Figure 
1. Adaptation of Model for Evidence-Based Practice Change)   
Step 1: Assess the need for change. A clinician’s interest in a practice change may 
stem from an awareness of patient or staff preferences or dissatisfaction, quality 
improvement data, practitioner queries, evaluation data, or new research data (Rosswurm 
& Larrabee, 1999).  During this phase, the clinician will identify the practice problem and 
notify key stakeholders, collect internal data, compare internal data to external data to 
confirm the need for a practice change, then link the problem, interventions and outcomes 
in a meaningful way (Larabee, 2009).  It is key during this phase to secure buy-in from 
key stakeholders to maximize likelihood of success.  Step two: Locate the best evidence.  
The clinician plans and conducts a literature search using key words from the clinical 
problem, intervention, and desired outcome.  During this step, the clinician uses a table of 
evidence or matrix for organizing data about the research studies.  Step three: Critically 
analyze the evidence.  In the critical appraisal of the literature, clinicians evaluate the 
strengths and weaknesses of studies and identify gaps and conflicts in the literature 
(Rosswurm & Larrabee, 1999).  Step four.  Design practice change. In the design phase, 
the clinician defines the proposed change, identifies the needed resources, and then 
designs the implementation and evaluation process (Larabee, 2009).  A proposed change 
may be in the format of a protocol, procedure, or standard.  Step five.  Implement and 
evaluate change in practice.  Actual implementation of the proposed change occurs in 
this step, but may be limited to a select number of patients if the clinician is part of a  
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Figure 1. Adaptation of Model for Evidence-Based Practice Change. (Larabee, 2009) 
	
Step 1: Assess need for practice change 
 
- Inconsistencies have been 
identified in the diagnosis and 
treatment of pediatric patients with 
short bowel syndrome and SBBO  
 
Step 2: Locate the best evidence 
 
- Develop PICOT question  
- Search Cochrane, CINAHL, and 
PubMed databases 
- Identify keeper articles 
	
Step 6: Integrate & maintain practice 
change 
 
- Implement clinical practice guide 
into standard practice within the 
division at project institution 
- Disseminate results to division 
through electronic communication 
and faculty meetings 
	
	
	
Step 3: Critically analyze the evidence 
 
- Diagnosis of SBBO in pediatrics is 
difficult due to complex testing 
methods 
- Diagnosis is often made based on 
risk factors and clinical symptoms  
- Interventional studies in pediatrics 
are limited 
- Treatment is based on clinical 
experience and favors antibiotic	
use	
Step 5: Implement & evaluate  
practice change 
 
- Develop clinical resource for 
identification & treatment of SBBO 
- Educate clinical staff 
- Evaluate use of clinical resource as 
a guide for identification & 
treatment of SBBO 
Step 4: Design practice change 
 
- Create an EBP project proposal 
- Create an EBP project timeline 
- Assess current clinical practices 
through retrospective chart 
review 
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larger organization.  Following the implementation, an evaluation of the process, 
outcomes, and costs is conducted.  Based on evaluation results, conclusions and 
recommendations can be made (Larabee, 2009).  Step six.  Integrate and maintain change 
in practice.  If the evaluation outcomes are favorable, steps are made to integrate the 
change into practice.  Recommended changes are communicated to the key stakeholders, 
the new process is integrated into a standard of care, and evaluation of outcomes 
continue.  Finally, dissemination of the project outcomes and recommendations to a 
wider audience such as in a peer reviewed publication is recommended.   
The Model for Evidence-Based Practice Change is a progressive, but not a linear 
process.  The bi-directional arrows between two steps indicate that activities in each step 
may stimulate activities in the other step (Larabee, 2009).  Following the steps of an 
evidence based model of change can lead to successful implementation and sustainment.  
Cincinnati Children’s Hospital Medical Center (CCHMC) endorses the use of evidence-
based decision making as a way to achieve the best and safest care for patients.  Patients 
and families expect clinical practice to be based on knowledge from current research in 
the field.  To support clinicians at CCHMC, the James M. Anderson Center for Health 
Systems Excellence was created to promote, guide, and support improvement work and 
health services research.  They also strive to spread the impact of such work into clinical 
practice and policy.			The Evidence-Based Decision Making (EBDM) process was created 
at CCHMC to integrate the best research or clinical evidence available with the clinical 
expertise and patient and family values to facilitate clinical decision making (CCHMC, 
2017).  
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The Evidence-Based Decision Making (EBDM) process consists of five steps and 
parallels the process established in the Model for Evidence-Based Practice Change.  Step 
one is the development of a clinical question in PICOT format.  PICOT is an acronym for 
the five components of a clinical question including population, intervention, 
comparison, outcome, and timeframe.  The clinical question is arguably the most 
important step in the process as a well-worded question is likely to yield the most 
relevant literature search results. 
Following the development of a PICOT formatted clinical question, a literature 
search is conducted using key components of the clinical question.  Once the literature 
search is completed, the critical appraisal process begins.  In step four, all relevant 
research is then summarized and consolidated into a synthesis table with an associated 
level and grade for each piece of evidence as well as a statement judging the strength of 
recommendations for practice change.  The final step of the EBDM process is the 
development of a care recommendation.  Care recommendations are based on the body of 
evidence available and other components for judging the strength of a recommendation.  
At CCHMC, evidence-based care recommendations may be presented as a BESt (Best 
Evidence Statement) or as Evidence-Based Care Guidelines (EBCG).  A BESt is shorter 
than an EBCG and contains clinical recommendations on a limited topic or single clinical 
question.  EBCG aim to answer multiple health or clinical questions regarding disease 
management and are designed to meet criteria for quality in the development of evidence-
based care recommendation statements from the National Guideline Clearinghouse and 
Appraisal of Guidelines for Research and Evaluation.  After an evaluation of the 
literature, review of current practices at CCHMC and collaboration with division leaders, 
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recommendations were prepared using BESt guidelines.  Preparation of the BESt 
document was guided by the CCHMC BESt Development Manual.  The manual is 
available for public viewing and can be accessed at 
https://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-
care/legend.	
Following the Model for Evidence-Based Practice Change, a clinical problem was 
identified and the need for practice change was established.  Key stakeholders were 
identified and supported the project.  The clinical problem was addressed using the 
interventions that will be described in the implementation section.  Planning and 
conducting a thorough literature search was the next step in the process and described 
herein.  Using the PICOT format, a clinical question was formulated to guide the 
literature search.  
PICOT Question 
The PICOT question used to guide the literature search for this project was: “In 
pediatric patients with short bowel syndrome presenting with signs and symptoms of 
SBBO, how does treatment with antibiotics compared to no treatment affect the 
symptoms of abdominal distention, vomiting and increased stool output?”  To further 
clarify the PICOT question, pediatric patients in this setting is defined as patients aged 
newborn through 18 years.  The signs and symptoms of SBBO are aligned with those 
listed above in the signs and symptoms section.  
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II.  EVIDENCE 
A literature search was conducted using key components of the PICOT question 
to find the best available evidence.  The search was conducted using Cochrane Database 
for Systematic Reviews, CINAHL and PubMed databases.  Keywords used and 
limitations applied are outlined in Appendix A.  Pediatric research in this field is limited, 
so the search was not restricted to only pediatric populations.  Additional articles were 
identified by hand searching the reference lists of reviewed articles.  Multiple articles 
were reviewed, 13 met the inclusion criteria for the project based on the PICOT question.  
Additional articles that provided information relevant to the clinical question in adult 
populations were used to support the findings in pediatric literature.  Background 
information was provided by articles not otherwise relevant to the clinical question, these 
were not critically appraised.  
Critical appraisal 
Once the literature search was complete, the critical appraisal process began.  The 
CCHMC Evidence Collaboration has developed and adapted tools for evaluating 
evidence known as the ‘Let Evidence Guide Every New Decision’ (LEGEND) system.  
Developed at CCHMC, the LEGEND system consists of six tools including a glossary of 
terms, table of evidence levels, algorithm to determine the study design, evidence 
appraisal forms, algorithm to grade the body of evidence, and templates regarding 
judging the strength of a recommendation (Clark, Burkett, & Stanko-Lopp, 2009). 
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The LEGEND system was selected for the critical appraisal of the literature.  
Each study is given a numeric value (1-5) based on the study design.  Number one 
represents the highest quality of research available such as a systematic review or meta-
analysis and number five represents lesser quality evidence such as expert opinion.  
Appendix B, Table of Evidence Levels, displays criteria for leveling research evidence.  
After determining the design of each study, LEGEND evidence appraisal forms were 
used to determine the quality level.  The evidence appraisal forms guide users through 
questions of validity, reliability and applicability to the clinical question.  LEGEND 
appraisal forms are specific to the study design and domain of the clinical question (Clark 
et al., 2009).  The quality of a study refers to the extent to which all aspects of the study 
design and conduct establish protection against bias.  Quality level “a” indicates good 
quality evidence and level “b” indicates lesser quality.  A quality level of not valid, 
reliable or applicable is an option for literature that does not answer the question of 
interest.  Appendix C, LEGEND critical appraisal forms, provides examples used for 
appraisal of expert opinion and systematic reviews.  
After leveling each individual study, the next step is grading the body of 
evidence.  This allows for consideration of the quality, quantity, and consistency of the 
body of evidence.  The quality of the body of evidence is assigned a grade of high, 
moderate, low or grade not assigned.  High grade indicates a sufficient number of high 
quality studies with consistent results.  Moderate grade indicates either multiple studies 
of lesser quality or with inconsistent results or a single well-done study.  Low grade 
refers to body of evidence consisting mostly of expert opinion, case reports, case studies 
and general reviews.  Grade not assigned is used when all of the studies are of 
	 	
	 21 
insufficient design or execution, too few studies, or inconsistent results within the body 
of evidence (Clark et al., 2009).  Appendix D, Grading the Body of Evidence forms, was 
used for grading the quality of the body of evidence.   
Evidence was then summarized and consolidated into a synthesis table.  Judging 
the strength of each practice recommendation was completed using the LEGEND system.  
Judging the strength of a recommendation consists of six dimensions including: grade the 
body of evidence, degree of harm to the patient, benefit to targeted population, burden on 
population to adhere to recommendation, cost-effectiveness to healthcare system, 
directness to the extent to which the body of evidence directly answers the clinical 
question and impact on morbidity, mortality, and quality of life.  The options for judging 
the strength of a recommendation using the LEGEND system are ‘strong 
recommendation’, ‘recommendation’, and ‘unable to make a recommendation’ (Clark et 
al., 2009).  Appendix E Judging the Strength of a Recommendation form was used to 
judge the overall strength of practice recommendations. 
The literature review focused on answering the clinical question about the 
effectiveness of antibiotic therapy to treat symptoms of SBBO in pediatric patients with 
short bowel syndrome.  Most of the supportive evidence came from expert opinion and 
review articles because randomized controlled trials investigating antimicrobial therapy 
to treat SBBO in pediatric patients with short bowel syndrome are scarce.  A summary of 
the pediatric literature can be found in Appendix F.  Clinicians often diagnose SBBO 
based on risk factors in combination with clinical presentation then recommend treatment 
with empiric antibiotics.  Goals of treatment should focus on correction of the underlying 
disease or structural defect, elimination of predisposing conditions, nutritional 
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replenishment and modification of the gastrointestinal microbiota by reducing or 
eliminating sluggish bowel motility and cleansing the bowel of pathogenic bacteria 
(Sieczkowska et al., 2016; Vanderhoof et al., 1998).  
Due to the lack of randomized clinical trials in children, there is not a specific 
approved therapy for small bowel bacterial overgrowth.  However, a variety of empiric 
antibiotics are used.  Appendix G contains a summary of commonly recommended 
antibiotic and non-antibiotic treatment options in pediatric patients.  Because there 
currently are no controlled trials studying the treatment of SBBO in pediatric patients 
with short bowel syndrome, recommendations are made on the basis of clinical 
experience.  
The most commonly recommended antibiotic choices include metronidazole, 
rifaximin, sulfamethoxazole/trimethoprim, and amoxicillin/clavulanic acid.  
Metronidazole is an absorbable antimicrobial agent and the most popular agent for 
eradicating anaerobes in this setting (Cole & Kocoshis, 2013).  Rifaximin, a non-
absorbable antimicrobial, also covers obligate anaerobes effectively and is frequently 
used.  Lack of insurance coverage and high costs make the use of rifaximin prohibitive 
for many patients.  Putrefactive, gram-negative aerobes may be treated with 
sulfamethoxazole-trimethoprim, oral gentamycin, extended-spectrum penicillin or 
cephalosporin therapy (Cole & Kocoshis, 2013).  Less common antibiotic choices include 
tobramycin, Colistin, chloramphenicol, clindamycin and vancomycin.  
Mirroring the findings in pediatric literature, metronidazole and rifaximin were 
the most commonly studied and recommended antibiotic choices to treat symptoms of 
SBBO in adults.  Summary and synthesis of the adult literature can be found in 
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Appendices H and I.  Di Stefano et al. (2005) studied the efficacy of metronidazole 
verses rifaximin in a group of adult patients with documented SBBO and short bowel 
syndrome.  The metronidazole group was prescribed 250 mg twice daily and the 
rifaximin group was prescribed 400 mg three times daily, each for a 7-day period.  While 
both antibiotics were effective, they found that metronidazole was more effective than 
rifaximin in reducing hydrogen breath excretion and gastrointestinal symptoms. 
 In a separate study by Lauritano et al. (2005), they examined the effectiveness of 
different doses of rifaximin in adult patients with positive breath tests and other 
predisposing conditions that result in symptoms of bloating, abdominal discomfort and 
diarrhea.  They found that a 1200 mg daily dose was associated with significantly higher 
therapeutic efficacy in eradication of symptoms than lower daily doses.  Lauritano et al. 
(2009) later studied the effectiveness of rifaximin 1200 mg daily versus metronidazole 
750 mg daily in patients with irritable bowel syndrome and symptoms of SBBO.  They 
found that rifaximin was associated with a higher decontamination rate based on pre and 
post breath tests (Lauritano et al., 2009).  The difference in efficacy of rifaximin between 
the three studies may be explained by the absence of short bowel syndrome in the latter 
two.  In order for rifaximin to be most efficient it must reach the site of bacterial 
overgrowth and achieve local concentration, suggesting that in short bowel syndrome 
these conditions may not be adequately satisfied making rifaximin less effective when 
compared to metronidazole in that population (Di Stefano et al., 2005).  
Attar et al. (1999) studied the effectiveness of norfloxacin, amoxicillin-clavulanic 
acid, and a probiotic in treating symptoms associated with SBBO.  Patients underwent 
five 7-day treatment periods including an untreated control period, placebo period, then 
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in random blinded fashion underwent a course of norfloxacin, amoxicillin-clavulanic 
acid, and Saccharomyces boulardii.  Results showed norfloxacin and amoxicillin-
clavulanic acid to be effective in treating overgrowth related diarrhea.  Although this 
study was limited by excluding pediatric patients, it provided useful information 
regarding symptom improvement on specific antibiotics and should be considered when 
making recommendations.  
Based on the LEGEND criteria for grading a body of evidence, the combined 
pediatric and adult evidence receives a moderate grading.  A moderately graded body of 
evidence contains multiple studies with varying strength of design and have relatively 
consistent results with minor exceptions.  Most of the supportive evidence comes from 
pediatric expert opinions or review articles, however included in this body of evidence is 
at least one systematic review and several adult cohort studies.  
Non-antibiotic recommendations include flushing the bowel with polyethylene 
glycol 3350, dietary modification, glutamine, probiotics, prokinetic agents, and surgical 
correction of underlying anatomic abnormalities (Ching et al., 2007; Cole & Ziegler, 
2007; Dehmer et al., 2011; DiBaise et al., 2006; Malik et al., 2011; Quigley & Quera, 
2006; Reed, 2014; Sentongo, 2008; Shah et al., 2013; Sieczkowska et al., 2016; 
Vanderhoof et al., 2003; Youssef et al., 2012).  Polyethylene glycol 3350 is a powder 
laxative commonly used to treat constipation.  After mixing per manufacturer 
recommendations, polyethylene glycol 3350 uses an osmotic effect to increase the 
amount of water in stool making it easy to pass.  Daily to weekly bowel flushes with 
polyethylene glycol 3350 have been proposed to reduce bacterial counts by removing 
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bacteria embedded in the mucosal lining (Reed, 2014).  Published studies assessing the 
effectiveness of polyethylene glycol 3350 for the use of treating SBBO were not found.  
Correction of micronutrient deficiencies and diet modification are valuable 
components of SBBO management.  Because most bacteria ferment carbohydrates, 
restriction of refined carbohydrates, such as concentrated sweets may aid in reducing 
osmotic diarrhea in this population.  Because many children with SBBO may have a 
reduction in the enzyme lactase related to the mucosal injury caused by the bacteria, 
avoiding lactose may help alleviate gastrointestinal discomfort.  Avoiding non-absorbable 
sugar alcohols, such as sorbitol and xylitol, may improve symptoms of flatulence and 
abdominal distention.  Due to the many restrictions, patients often benefit from a low 
carbohydrate, high fat diet for optimal control of symptoms (Reed, 2014).  
Glutamine is a nonessential amino acid and the primary source of energy for the 
enterocyte, the cell of the intestinal lining.  Glutamine has been shown to prevent 
mucosal atrophy and deterioration in gut permeability in animal models and in adults 
who are receiving parenteral nutrition.  In adults, glutamine has been shown to improve 
the growth and function of the human gut epithelial cells when used in combination with 
human growth hormone and a high-fiber, low-fat diet.  Data in children is inconclusive at 
this time and requires additional studies to ensure efficacy and safety (Dehmer et al., 
2011).  
Probiotics are defined as live microorganisms that provide health benefits to the 
host when ingested.  Many varieties are available, but few have undergone adequate 
testing in pediatric clinical trials.  The use of probiotics for treatment for SBBO is based 
on the premise that the probiotic will compete with pathogenic bacteria, prevent bacterial 
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translocation, and enhance mucosal barrier (Reed, 2014).  The risk to benefit ratio of 
probiotics, especially in children with immature immune systems and indwelling central 
venous catheters, have been debated in medical literature.  Septic episodes due to 
probiotic organisms have been documented leading to avoidance of probiotics in 
pediatric patients with central venous catheters (Malik et al., 2011; Youssef et al., 2012).  
For patients with short bowel syndrome and an intact colon, the use of probiotics that 
produce D-lactate increase the risk of developing the life-threatening condition, D-lactic 
acidosis (DiBaise et al., 2006; Youssef et al., 2012).   
Prokinetic therapy has been suggested to increase the motility of the bowel 
thereby decreasing stasis and potential for bacterial overgrowth.  Prokinetic agents such 
as metoclopramide, erythromycin, and cisapride have been shown to promote motility in 
these patients but their use is restricted due to potentially harmful side effects.  
Metoclopramide is a central and peripheral dopamine type 2 receptor antagonist that has 
a variety of central nervous system side effects including dystonic reactions, 
extrapyramidal side effects, and tardive dyskinesia (Ching et al., 2007).   
Erythromycin has been used as a motilin receptor agonist and is associated with 
various drug interactions.  Cisapride, a 5-HT3 agonist, is associated with serious cardiac 
arrhythmias and sudden death.  Since 2000, cisapride has been part of an FDA-mandated 
limited-access protocol due to concerns of serious adverse cardiac events and can only be 
prescribed by providers who met strict criteria (Ching et al., 2007).  
Finally, surgical correction of an underlying anatomic anomaly has been 
suggested as treatment for SBBO.  Surgery is normally considered when severe 
symptoms recur despite adequate medical therapies.  Surgical correction of anatomic 
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anomalies leading to stasis and proliferation of bacteria can be immediately corrective for 
SBBO symptoms (Sentongo, 2008).  
Regardless of the measures used, many therapies either pose risk for 
complications or become ineffective with time.  Current antibiotic treatments are based 
on scientific theory which favor gram negative and anaerobic antibiotics.  Antibiotics are 
chosen based on the bacteria presumed to cause the symptoms and based on clinical 
experience.  The most commonly studied and recommended antibiotics in pediatrics and 
adult literature are metronidazole and rifaximin. 
Clinical Knowledge Gaps 
Despite the availability of clinical expert opinions and descriptive studies 
regarding the use of antibiotic therapy for the treatment of SBBO, there remains a large 
gap in pediatric clinical trials.  A number of the pediatric expert opinions, adult 
interventional studies and adult expert opinions discuss medications not commonly 
prescribed in current management of clinical SBBO; however, those medications studied 
did result in significant improvement in clinical symptoms correlated by improvement in 
diagnostic testing results (Attar et al., 1999; Di Stefano et al., 2005; Lauritano et al., 
2005; Lauritano et al., 2009).  Pediatric clinical trials are needed to fully understand the 
role of antibiotics as a means to treat symptoms caused by SBBO.  
Statement of Recommendations 
After a thorough review and critical appraisal of the literature, recommendations 
for practice were developed.  Consistent with the LEGEND system, the strength of each 
recommendation was evaluated using the Judging the Strength of a Recommendation 
tool.  It was strongly recommended that providers properly identify risk factors for 
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SBBO.  Learning to identify risk factors has the potential for significant benefit to this 
population in terms of morbidity, mortality and quality of life.  The evidence presented to 
support this recommendation is largely based on expert opinion, clinical experience, and 
literature review, as well as the limited pediatric research available (Bohm et al., 2013b; 
L. Chan, Parrish, & DiBaise, 2015; Ching et al., 2007; Cole & Ziegler, 2007; Collins & 
Lin, 2011; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et al., 2006; Gutierrez et 
al., 2012; Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014; 
Vanderhoof et al., 2003).  Knowing the risk factors for SBBO, has the potential to 
minimize overprescribing of unnecessary antibiotics.  Overprescribing leads to increased 
healthcare expenses while failure to comply with antibiotic stewardship increases risk of 
multi-resistant organisms.  
Second, it was strongly recommended that providers receive educational training 
in the identification of the signs and symptoms of SBBO (Bohm et al., 2013b; L. Chan et 
al., 2015; Ching et al., 2007; Cole & Ziegler, 2007; Collins & Lin, 2011; Dehmer et al., 
2011; Di Stefano et al., 2005; DiBaise et al., 2006; Gutierrez et al., 2012; Lauritano et al., 
2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014; Vanderhoof et al., 2003).  
Identifying the signs and symptoms of SBBO also has the potential to have great impact 
on the quality of life for those affected.  Differentiating the signs and symptoms of SBBO 
from other etiologies will allow providers to more quickly recognize when an antibiotic 
therapy is indicated and when it is not.  
Finally, it is recommended that providers receive educational training in the 
identification of suitable antibiotics and doses for the treatment of SBBO (Attar et al., 
1999; Bohm et al., 2013b; L. Chan et al., 2015; Ching et al., 2007; Cole & Kocoshis, 
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2013; Cole & Ziegler, 2007; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et al., 
2006; Lauritano et al., 2005; Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 
2006; Reed, 2014; Sentongo, 2008; Shah et al., 2013; Sieczkowska et al., 2016; 
Vanderhoof et al., 1998; Vanderhoof et al., 2003; Youssef et al., 2012).  This 
recommendation was given a strong recommendation.  Based on the multitude of clinical 
experiences, expert opinion, and the limited number of interventional studies available, 
there is a support for a handful of specific antibiotics which have been shown to be 
effective in minimizing symptoms.  Appendix J Completed Judging the Strength of a 
Recommendation form, provides an overview of the strength of the three practice 
recommendations.  After completing a review of current practices, a finalized list of 
preferred antibiotics has been generated with the assistance of the collaborating 
stakeholders.  The preferred antibiotic list will be become part of the BESt document 
used by providers caring for patients with suspected SBBO.  
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III.  IMPLEMENTATION 
Project Setting and Population 
Cincinnati Children’s Hospital Medical Center (CCHMC) was the setting for the 
project.  It is one of the oldest and most distinguished pediatric hospitals in the United 
States with more than 600 registered beds.  Support for the project was obtained by the 
Clinical Director of the Division of Gastroenterology, Hepatology, and Nutrition and 
agency approval granted by the Vice President of Patient Services (Agency approval 
form, Appendix K).  CCHMC is second best pediatric hospital in the nation according to 
the 2018-2019 U.S. News and World Report.  Among those standings, Gastroenterology 
ranked number three as a result of their dedication and ability to provide comprehensive 
care to children with all levels of need (CCHMC, 2018).  
Within the Division of Gastroenterology, Hepatology and Nutrition, the Intestinal 
Care Center (ICC) exists to provide consultation, management, and long-term follow up 
for children with enteral feeding tube dependence, central venous catheters with 
parenteral nutrition requirements, intestinal failure and short bowel syndrome.  Despite 
the clear dedication to improving health outcomes for children, the ICC has not 
developed a resource to assist providers in the identification and treatment of SBBO in 
pediatric patients with short bowel syndrome.
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The population of interest included pediatric patients (age newborn -18 years old) 
with a diagnosis of short bowel syndrome secondary to omphalocele, gastroschisis, 
duodenal atresia, jejunal atresia, ileal atresia, necrotizing enterocolitis, malrotation with 
volvulus, Hirschsprung’s disease or traumatic bowel injury who received treatment at 
CCHMC on the inpatient Gastroenterology Lumen service between 5/1/2016-5/1/2017.  
All patients who met the inclusion criteria were considered. Patients who did not meet 
inclusion criteria were not included.  
Most patients admitted to the Gastroenterology Lumen service are housed on 
A4S, a 24-bed unit specializing in the complex care of gastrointestinal and surgical 
patients.  Patients admitted to the inpatient Gastroenterology Lumen service are managed 
by Nurse Practitioners and second year resident physicians with oversight by a first-year 
Gastroenterology fellow physician and an attending physician.  The ICC followed more 
than 200 patients who had the potential to be admitted during the project timeframe.  
IRB determination and HIPAA compliance 
Appropriate regulatory approval was required from both CCHMC and Wright 
State University (WSU) to conduct a retrospective chart review.  The IRB at CCHMC 
must review all research involving human participants as defined by CCHMC policy in 
accordance with federal regulations, applicable state laws and institutional policy.  
Application for IRB determination at CCHMC was submitted through the institutions’ e-
PAS website.  All named project participants completed Collaborative Institutional 
Training Initiative (CITI) training and conflict of interest statements in accordance with 
IRB determination.  Approval from WSU for retrospective chart review was requested 
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using their regulatory process.  Determination from CCHMC and WSU IRBs was 
received in summer 2017 (Appendix L and M).  
Every effort was made to maintain HIPAA (Health Insurance Portability and 
Accountability Act) compliance and protect patient privacy throughout the project.  The 
DNP student and Information Services personnel were the only individuals with access to 
the patient names linked with protected patient information.  Protected patient 
information included patient name, electronic health record number, gender, age, date of 
admission, diagnosis, presence of enteral feeding tubes or central venous catheters, 
presence of risk factors, clinical symptoms, means of diagnosis, treatment, and 
consequences.  
All data was saved using a military grade hardware encrypted flash drive.  The 
flash drive was utilized to store project data.  Data on the flash drive was separated into 
two files.  The first file was the initial report provided by the Department of Information 
Services displaying patient name, electronic health record number, diagnosis and date of 
admission.  The second file was converted to include a randomized identifier and the 
remainder of the data collection results.  Each file was protected by its’ own unique 
password.  Only the DNP student had access to the password of the first file that included 
patient identifiers.  When not in use, the flash drive was kept in a locked filing cabinet in 
the DNP student’s office.  In the event that data had to be sent via electronic mail, the 
message was sent from the DNP student’s CCHMC Outlook server and encrypted using 
the prefix ‘zix:’ in the subject line of the message, which ensured encryption.  All project 
findings were reported in aggregate.  
Implementation plan 
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 A one year retrospective chart review of qualifying pediatric patients on the 
Gastroenterology Lumen service was planned to establish the role of antibiotic therapy as 
treatment for small bowel bacterial overgrowth in pediatric patients with short bowel 
syndrome using an evidence-based approach.  There were two specific aims for this 
project.  The first aim was to increase provider knowledge about the risk factors for small 
bowel bacterial overgrowth, the signs and symptoms consistent with small bowel 
bacterial overgrowth, and the preferred antibiotic treatment options when clinically 
indicated.  The second aim was to develop a BESt document reflective of the 
recommendations derived from this project for institutional use.  
Identification of resources 
The project team consisted of a project chair, project lead, a gastroenterology 
physician, infectious disease physicians, a statistician, a pharmacist, an evidence-based 
practice mentor, and support personnel.  Table 1 summarizes the project team, their role 
and their home agency.  The DNP student served as the project lead and assumed the 
majority of the project related responsibilities as well as provided oversight of the tasks 
assigned to other team members.  The project lead provided the conceptual design for the 
project, conducted and summarized a review of the literature, secured necessary 
regulatory determinations from the Institutional Review Boards (IRB) at CCHMC and 
WSU, determined the data search parameters, designed the data collection tool, 
performed chart review and data collection, reviewed results with project team, and 
drafted the proposal for the BESt document prior to submission.   
The gastroenterology and infectious disease physicians provided content 
expertise, reviewed current practices as discovered through chart review and provided  
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Table 1.  
Project team	
Name Role Agency 
Christie Heinzman Project Lead/DNP Student 
 
 
Wright State University 
 
Tracy Brewer Project Chair/DNP Mentor 
 
 
Wright State University 
 
Conrad Cole Gastroenterology Physician  Cincinnati Children’s 
Hospital Medical Center 
 
Heidi Anderson Antibiotic Stewardship Physician Cincinnati Children’s 
Hospital Medical Center 
 
David Haslam Antibiotic Stewardship Physician Cincinnati Children’s 
Hospital Medical Center 
 
Josh Courter Antibiotic Stewardship Pharmacist Cincinnati Children’s 
Hospital Medical Center 
 
Emily Acker Staff Pharmacist Cincinnati Children’s 
Hospital Medical Center 
 
Mike Bottomley Senior Statistical Consultant Wright State University 
 
 
Mary Ellen Meier EBP/BESt Mentor Cincinnati Children’s 
Hospital Medical Center 
   
	
assistance in drafting the BESt proposal document.  The statistician reviewed all data and 
provided assistance with data analysis.  The pharmacist provided expertise in pediatric 
appropriate dosing for off-label use of medications and reviewed the proposed BESt draft 
document.  Support personnel were enlisted to generate an electronic medical record 
(EMR) report based on search parameters provided by the project lead.  The evidence-
based practice mentor provided guidance and support throughout the duration of the 
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project.  The project chair, Dr. Tracy Brewer, provided the DNP student with oversight, 
counsel, and support during the implementation and evaluation phases of the project. 
Project implementation 
The project concept, design and review of literature was presented during the 
proposal phase.  The remainder of the project was completed in several phases.  After 
IRB determination, the Department of Information Services at CCHMC was asked to 
perform a query report of the EMR system for patient admissions between 5/1/2016-
5/1/2017 with a diagnosis of short bowel syndrome, omphalocele, gastroschisis, duodenal 
atresia, jejunal atresia, ileal atresia, necrotizing enterocolitis, malrotation with volvulus, 
and intestinal pseudo-obstruction using ICD-10 diagnosis codes.  The report was 
provided to the project lead and used to guide the chart review.  A data collection tool 
was used to collect data during chart review (Appendix N).  
The data collection tool consisted of five sections including demographics, risk 
identification, diagnostic measures, treatment measures, and sequelae.  The demographic 
section included patient gender, age, admission date, discharge date and survival status at 
three months post admission and at the completion of the review period.  The risk 
identification section tracked the diagnosis and underlying condition, co-morbid 
conditions, presence of a central venous catheter, route of enteral feeds, presence of risk 
factors for SBBO, and presence of signs and symptoms of SBBO.   
Assessment of risk factors and signs and symptoms was based on the conditions 
presented in the literature synthesis table (Appendix O).  Diagnostic measures assessed 
the method of diagnosing SBBO including hydrogen breath testing, duodenal aspirate, 
small bowel biopsy, or clinical suspicion.  Assessment of treatment tracked if an 
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antibiotic was prescribed with the intent to treat SBBO, which antibiotic was prescribed 
and its dosing regimen, as well as the costs for the treatment course.  Sequelae of interest 
included resolution of symptoms and occurrence of central line associated-blood stream 
infection (CLA-BSI) within three months of antibiotic course.  If there was a subsequent 
CLA-BSI, the organism was tracked as well as the antibiotic used to treat the preceding 
SBBO, the need for central venous catheter removal and its associated length of 
hospitalization.  
The chart review data was then reviewed and analyzed in collaboration with the 
statistical team at WSU.  The detailed data analysis was discussed with the physician 
mentors.  The antibiotic stewardship team was brought in to review the analysis and 
provide expert opinion.  Following that discussion, recommendations for the BESt 
document were finalized. 
A BESt document has been drafted by the project lead with contributions from 
key stakeholders and will be submitted to the BESt for Evidence Collaboration Review 
committee by August 15, 2018 (Appendix P).  Approval is anticipated to take up to 120 
days from submission, approximately five months following the project defense.  Project 
timeline can be found in Appendix Q.  The project lead is currently developing education 
materials to be distributed to the clinical staff including Registered Nurses (RN), 
Advance Practice Registered Nurses (APRN), resident, fellow and attending physicians.  
Education materials will be finalized within 30 days following the final approval of the 
BESt document by the review committee.  Materials will include slide show 
presentations that discuss the risk factors for SBBO, signs and symptoms of SBBO, as 
well as a reference guide for treatment of SBBO.   
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After the approval of the BESt document, education materials will be distributed 
to clinical staff including RNs, APRNs, as well as resident, fellow and attending 
physicians.  Following the dissemination of educational materials, the bedside RN will be 
asked to monitor the patients’ clinical status and document symptoms consistent with 
SBBO.  The APRN, resident, fellow and attending physicians will assess patients for 
presence of SBBO and initiate treatment if indicated according to the BESt 
recommendations.  Additionally, providers will assess the need for continued SBBO 
treatment in patients who are admitted on a prophylactic cycle of antibiotics.  Physicians 
and APRNs will ensure proper clinical documentation of symptoms and response to 
treatment, management of EMR clinical problem list, and ensure correct diagnosis coding 
for chief and comorbid conditions.  Finally, dissemination of the project including a 
summary of the evidence, summary of clinical practice habits during the timeframe 
reviewed, and education materials will be disseminated to the entire division within 60 
days following final acceptance of the BESt proposal.  
Stakeholders and facilitators to implementation 
The success of a clinical endeavor of such magnitude was highly dependent on 
the support of the system, especially from those who are dedicated to the implementation 
of the project.  CCHMC’s organizational commitment to safety and quality improvement 
contributed to success of this project.  When considering members for inclusion into the 
interdisciplinary project team, recruitment was focused on those who are passionate about 
the patient population, outcome measures, cost reduction, and evidence-based practices.  
Success of the project was dependent on the support and cooperation of all stakeholders 
and team members.   
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Barriers to implementation 
Major barriers to implementation were not expected but did arise as the project 
developed.  Receiving determination from either IRB was not an initial anticipated 
barrier.  However due to staffing issues at WSU, IRB determination was delayed by more 
than three months which significantly delayed the progress of the project.  The intent was 
to have the BESt document finalized and published by the defense of this evidence-based 
project.  Due to the time constraints of the WSU IRB, there was an unexpected delay and 
only the retrospective chart review, data analysis, and draft development of the BESt 
could be completed by the final defense.   
Evaluation 
 Data was collected using a data collection tool (Appendix N).  The data collection 
tool was developed in Excel by the project lead.  Excel spreadsheets can be used for 
collecting and summarizing raw data (Microsoft, 2018).  Data was summarized and 
analyzed in collaboration with a statistical consultant at WSU.  An alpha=0.05 was 
selected to determine the level of significance during the analysis. SAS version 9.4 
software was used for all analyses.   
Outcome measures 
Data was collected by retrospective chart review for specific demographic variables 
and to determine outcomes for nine specific project questions important in developing the 
BESt document.  Method for statistical analysis was determined after consultation with 
the Statistical Consulting Center at WSU.   
1. Does the use of an antibiotic for presumed SBBO lead to more CLA-BSI?  To 
answer this question, a mixed effects logistic regression was done.  The 
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prevalence of CLA-BSI within three months among children who had and did not 
have antibiotic treatment for SBBO was reviewed as well.  
2. Do specific symptoms of SBBO lead to antibiotic treatment more often than 
others?  A mixed effects logistic regression was performed to answer this 
question. 
3. Is there a relationship between the presence of CLA-BSI and the patient’s age?  
Mixed effects logistic regression was performed to answer this question. 
4. Are there differences in the number of symptoms between patients who are 
treated with antibiotics for SBBO and those who are not?  A mixed effects 
negative binomial regression was performed to answer this question.  
5. Do patients being treated with antibiotics for SBBO have a shorter length of stay 
than those who are not receiving antibiotics?  A shared frailty Cox proportional 
hazards model was performed to answer this question.  
6. Do patients being treated with antibiotics for SBBO have a higher rate of 
resolution of symptoms than those who are not receiving antibiotics?  A simple 
count for the visits with known resolutions of symptoms was performed to answer 
this question.  
7. How many of the reviewed patients (in terms of visits) were prescribed antibiotics 
who did not meet the criteria for risk factors for SBBO or have signs/symptoms of 
SBBO?  Of these, how many antibiotics exposed days were there?  What was the 
costs of the antibiotics?  Descriptive analysis was used to answer these questions. 
8. Of the reviewed patients (in terms of visits) who received antibiotic treatment for 
SBBO, how many developed a CLA-BSI within three months?  What SBBO 
	 	
	 40 
antibiotic was used?  What organism/s grew?  Did the central venous catheter 
have to be removed?  If the line was removed, how many additional days did the 
patient stay in the hospital?  Descriptive statistics were used to answer these 
questions.  
9. Do patients with certain anatomic risk factors who are treated with antibiotics for 
SBBO have CLA-BSI more frequently than patients with other anatomic risk 
factors?  A mixed effects logistic regression was used to answer this question.  
Table 2 provides an explanation of specific outcome measures, variable codes and 
associated data collection methods. 
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Table 2.  
Explanation of data variables 
Topic 
 
Measure Code 
 
Variable 
 
Collection method 
DEMO1 Patient ID number PT ID Numeric Assigned 
 
DEMO2 Gender DGEN 1=M 
2=F 
Chart review 
 
DEMO3 Patient date of birth DDOB 00/00/0000 Chart review 
 
DEMO4 Age at admission 
 
DAGE # Chart review 
DEMO5 Admit date DADMIT 00/00/0000 Chart review 
 
DEMO6 
 
DEMO7 
 
DEMO8 
 
 
DEMO9 
 
Discharge date 
 
Length of stay 
 
Survived at 3 months  
post admission 
 
Survived at end of study 
DDC 
 
LOS 
 
SUR3MO 
 
 
SUREND 
00/00/0000 
 
Numeric 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
Chart review 
 
Calculated 
 
Chart review 
 
 
Chart review 
RISK1 Primary diagnosis RPDIAG ICD-10 code Chart review 
 
RISK2 Secondary diagnosis RSDIAG ICD-10 code Chart review 
 
RISK 3 Additional diagnosis RSDIAG2 ICD-10 code Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
 
RISK4 
 
RISK5 
 
RISK6 
 
RISK7 
 
Additional diagnosis 
 
Additional diagnosis 
 
Additional diagnosis 
 
Additional diagnosis 
 
RSDIAG3 
 
RSDIAG4 
 
RSDIAG5 
 
RSDIAG6 
 
ICD-10 code 
 
ICD-10 code 
 
ICD-10 code 
 
ICD-10 code 
 
Chart review 
 
Chart review 
 
Chart review 
 
Chart review 
 
 
RISK8 Presence of central venous 
catheter 
 
RCVC 1=yes 
2=no 
Chart review 
RISK9 
 
 
RISK10 
 
 
RISK11 
 
 
RISK12 
 
 
RISK13 
 
 
 
Oral nutrition 
 
 
Enteral nutrition 
 
 
Parenteral nutrition 
 
 
Short bowel syndrome 
 
 
Abdominal wall defect 
(gastroschisis or 
omphalocele) 
 
RFEEDPO 
 
 
RFEEDEN 
 
 
RFEEDIV 
 
 
ANT1 
 
 
ANT2 
 
 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
RISK14 
 
 
 
RISK15 
 
 
RISK16 
 
 
RISK17 
 
RISK18 
 
 
RISK19 
 
 
RISK20 
 
 
 
 
RISK21 
 
 
RISK22 
 
 
Small bowel atresia 
(duodenal, jejunal, or 
ileal) 
 
Necrotizing enterocolitis 
 
 
Malrotation with or  
without volvulus 
 
Hirschsprung’s disease 
 
Presence of an ostomy 
 
 
Dysmotility 
 
 
Chronic intestinal pseudo- 
Obstruction or Megacystic  
Microcolon Intestinal 
Hypoperistalsis Syndrome 
 
Radiation enteropathy 
 
 
H. pylori 
 
 
ANT3 
 
 
 
ANT4 
 
 
ANT5 
 
 
ANT6 
 
ANT7 
 
 
FUNC1 
 
 
FUNC2 
 
 
 
 
FUNC3 
 
 
FUNC4 
 
 
1=yes 
2=no 
 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
Chart review 
 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
Chart review  
 
 
Chart review 
 
 
Chart review 
 
 
 
 
Chart review 
 
 
Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
RISK23 
 
 
RISK24 
 
 
RISK25 
 
 
RISK26 
 
 
RISK27 
 
 
RISK28 
 
 
RISK29 
 
 
RISK30 
 
 
RISK31 
 
 
RISK32 
 
Proton pump inhibitor use 
 
 
Hypochlorhydria 
 
 
Total or subtotal 
gastrectromy 
 
Immunodeficiency  
 
 
Malnutrition 
 
 
Chronic pancreatitis 
 
 
Total parenteral nutrition 
 
 
Nausea/vomiting 
 
 
Dehydration 
 
 
Abdominal pain 
 
FUNC5 
 
 
FUNC6 
 
 
FUNC7 
 
 
MULTI1 
 
 
MULTI2 
 
 
MULTI3 
 
 
MULTI4 
 
 
SIGNS1 
 
 
SIGNS2 
 
 
SIGNS3 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
 
RISK33 
 
 
RISK34 
 
 
RISK35 
 
 
RISK36 
 
 
RISK37 
 
Distention/bloating/gas 
 
 
Diarrhea/steatorrhea 
 
 
Hematochezia 
 
 
Weight loss 
Malabsorption 
 
Metabolic acidosis 
 
SIGNS4 
 
 
SIGNS5 
 
 
SIGNS6 
 
 
SIGNS7 
 
 
SIGNS8 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
Chart review 
 
 
 
DIAG1 Diagnostic method DMETH 1=Other method including 
breath test, DNA PCR, duodenal 
aspirate or small bowel biopsy 
5=Clinical suspicion 
6=Prior to admission med 
 
Chart review 
TREAT1 Treatment administered TGIVEN 1=Yes 
2=No 
3=Prior to admission 
medication stopped at  
discharge 
 
Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
TREAT2 Antibiotic prescribed TABX 1=Amphotericin 
2=Amoxicillin-Clavulanic acid 
3=Cephalosporin 
4=Ciprofloxacin 
5=Chloramphenicol 
6=Clindamycin 
7=Colistin 
8=Doxycycline 
9=Gentamicin 
10=Metronidazole 
11=Neomycin 
12=Norfloxacin 
13=Rifaximin 
14=Tetracycline 
15=Tobramycin 
16=Trimethoprim/sulfa 
17=Vancomycin 
18=Nitazoxanide  
 
Chart review 
TREAT3 Treatment dose prescribed TREGIMEN Descriptive Chart review 
 
 
TREAT4 Cost of antibiotic 
treatment 
 
TCOST Number value Inpatient pharmacy 
TREAT5 Second antibiotic 
prescribed 
TABX2 1=Amphotericin 
2=Amoxicillin-Clavulanic acid 
3=Cephalosporin 
4=Ciprofloxacin 
Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
5=Chloramphenicol 
6=Clindamycin 
7=Colistin 
8=Doxycycline 
9=Gentamicin 
10=Metronidazole 
11=Neomycin 
12=Norfloxacin 
13=Rifaximin 
14=Tetracycline 
15=Tobramycin 
16=Trimethoprim/sulfa 
17=Vancomycin 
18=Nitazoxanide  
 
TREAT6 Treatment dose prescribed TREGIMEN2 Descriptive Chart review 
 
 
TREAT7 Cost of antibiotic 
treatment 
 
TCOST2 Number value Inpatient pharmacy 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
SEQ1 
 
 
SEQ2 
	
	
	
SEQ3 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
SEQ4 
	
	
	
Documented resolution of 
symptoms 
 
CLA-BSI within three 
months of treatment for 
SBBO 
 
If SEQ2 is yes, what 
antibiotic was prescribed 
for SBBO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If SEQ2 is yes, what 
organism grew 
 
 
 
SEQRES 
 
 
SEQCLABSI 
 
 
 
SEQCLAABX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEQCLAORG 
 
 
 
 
1=yes 
2=no 
 
1=yes 
2=no 
 
 
1=Amphotericin 
2=Amoxicillin-Clavulanic acid 
3=Cephalosporin 
4=Ciprofloxacin 
5=Chloramphenicol 
6=Clindamycin 
7=Colistin 
8=Doxycycline 
9=Gentamicin 
10=Metronidazole 
11=Neomycin 
12=Norfloxacin 
13=Rifaximin 
14=Tetracycline 
15=Tobramycin 
16=Trimethoprim/sulfa 
 
1=Staph 
2=Strep 
3=Enterococcus 
4=Klebsiella 
5=Candida 
Chart review 
 
 
Chart review 
 
 
 
Chart review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart review 
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Topic 
 
Measure Code 
 
Variable 
 
Collection method 
 
 
SEQ5 
 
 
 
 
 
 
SEQ6 
 
 
SEQ7 
	
 
 
 
Second organism grown 
 
 
 
 
 
 
If SEQ2 is yes, was 
central line removed 
 
If SEQ2 is yes, how long 
was subsequent hospital 
stay 
 
 
 
SEQCLAORG2 
 
 
 
 
 
 
SEQREMCVC 
 
 
SEQLOA 
6=Other  
 
1=Staph 
2=Strep 
3=Enterococcus 
4=Klebsiella 
5=Candida 
6=Other 
 
1=Yes 
2=No 
 
Numeric value 
 
 
 
Chart review 
 
 
 
 
 
 
Chart review 
 
 
Chart review 
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IV. FINDINGS 
This evidence-based project was successful in creating a new body of knowledge 
related to the use of antibiotic therapy for the treatment of SBBO in pediatric patients 
with short bowel syndrome.  Due to limitations of the sample size, not all of the outcome 
measures were able to be analyzed.  During the specified timeframe of interest, 146 
hospital admission visits were reviewed representing 83 unique patients.  Each hospital 
admission was counted as one visit.  Some patients had more than one visit during the 
timeframe of interest, which explains the numerical difference between visits and 
patients.   
Demographics 
Approximately 65% of the patients were male compared to 35% female.  The age 
of the patients ranged from birth to 18 years of age (M = 6.94, SD = 5.11).  Patient 
survival at three months post admission and at the conclusion of the review period was 
the same at 98.6%.  This finding represents two patients that died during hospitalization. 
Table 3 summarizes the demographic data.  
Risk Factors 
  Of the 146 admission visits, a patient presented with an indwelling central venous 
catheter at admission more than half of the time (n=97). This was the leading risk factor.  
The most common anatomic risk factor was short bowel syndrome (n=79), followed by 
presence of an ostomy, intestinal malrotation, Hirschsprung’s disease, necrotizing 
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enterocolitis, small bowel atresias and abdominal wall defects including gastroschisis and 
omphalocele.   
Table 3.  
Demographic data 
Variable Count Frequency 
 
Encounters 
Hospital admissions 
Unique patients 
 
 
 
146 
83 
 
 
 
 
 
Gender 
Male 
Female 
 
95 
51 
 
64.38% 
35.62% 
 
Age in years 
Mean 
SD 
Range 
 
 
6.94 
5.11 
0-18 
 
 
Patient survival 
Alive on admission 
Alive at 3 months post 
admission 
Alive at end of review 
period 
 
 
146 
 
144 
 
144 
 
 
100% 
 
98.6% 
 
98.6% 
 
Some patients had more than one anatomic risk factor.  The most common functional risk 
factor was PPI use (n=72), followed by intestinal dysmotility, then chronic intestinal 
pseudo-obstruction and megacystis microcolon intestinal hypoperistalsis syndrome.  The 
most common multi-factorial risk factor for SBBO was TPN use (n=85), followed by 
malnutrition, immune deficiency and chronic pancreatitis.  Table 4 summarizes the 
prevalence of risk factors.   
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Table 4.  
Prevalence of risk factors 
Risk factor Count (n) Prevalence 
Presence of a central line 
 
Anatomic risk factors 
97 
 
 
66.0% 
 
 
Short bowel syndrome 
 
Presence of an ostomy 
79 
 
43 
54.11% 
 
29.5% 
   
Intestinal malrotation 39 26.7% 
   
Hirschsprung’s disease 32 21.9% 
   
Necrotizing enterocolitis 29 19.8% 
   
Small bowel atresias 24 16.4% 
   
Abdominal wall defects 21 14.3% 
 
 
Functional risk factors 
  
Proton pump inhibitor use 
 
Intestinal dysmotility 
72 
 
70 
49.3% 
 
47.9% 
   
CIPO & MMIHS 30 20.5% 
   
Radiation enteropathy 0 0.00% 
 
Hypochlorhydria 0 0.00% 
   
Prior gastrectomy 0 0.00% 
 
 
Multi-factorial risk factors 
  
TPN dependence 85 58.3% 
   
Malnutrition 38 26.0% 
   
Immune deficiency 6 4.10% 
   
Chronic pancreatitis  1 0.68% 
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Antibiotics  
The four most commonly prescribed antibiotics for SBBO were metronidazole, 
nitazoxanide, rifaximin, and sulfamethoxazole/trimethoprim.  Several other antibiotics 
were also used for SBBO.  Non-antibiotic methods were not used.  Table 5 summarizes 
all of the antibiotics prescribed for SBBO during the chart review period.  
Table 5.  
Antibiotics prescribed for SBBO 
Antibiotic Count (n) Prevalence 
metronidazole 
 
34 65.0% 
 
nitazoxanide 6 11.5% 
   
rifaximin 5 9.62% 
   
sulfamethoxazole/trimethoprim 4 7.69% 
   
amoxicillin-clavulanic acid 2 3.85% 
   
vancomycin 1 1.92% 
	
Outcome Questions  
 Does the use of an antibiotic for presumed SBBO lead to more CLA-BSI?  
For each of the patients in the chart review, it was noted whether they had a central 
venous catheter, if it became infected within three months of admission and if they were 
prescribed antibiotics for SBBO.  Any patient without a central venous catheter was 
excluded from this portion of the analysis (n=49).  Two patients were already taking an 
antibiotic upon admission to the hospital and were also excluded from the analysis.  Since 
patients could be admitted to the hospital more than once during the given year, a random 
subject effect was included to account for any correlations between admissions by the 
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same patient.  A mixed effects logistic regression was used for this analysis.  Mixed 
effects mean there are both fixed and random effects (Upton & Cook, 2014).  In this case, 
the fixed effect is “antibiotic use” and the random effect is a “CLA-BSI”.  The mixed 
effects logistic regression model yielded a p-value of 0.15, which was not sufficient to 
suggest a statistically significant association between antibiotic use and CLA-BSI.  Table 
6 shows the relationship between antibiotic use for SBBO and resultant CLA-BSI.  
Table 6.  
CLA-BSI counts by antibiotic status   
Use of antibiotic for SBBO Subsequent CLA-BSI  
 Yes Frequency No Frequency N/Total % 
Yes 7 20% 28 80% 35/100% 
No 21 35% 39 65% 60/100% 
Total 28  67  95/100% 
	
 Do specific symptoms of SBBO lead to antibiotic treatment more often than 
others?  To answer the question regarding the relationship between the presence of 
specific symptoms and antibiotic prescribed upon admission, a mixed effect multiple 
logistic regression was used.  Again, a random subject effect was included to account for 
multiple admissions by the same patient.  Two patients were excluded from the analysis 
since they were already taking an antibiotic upon admission (n=144).  In this case, the 
fixed effect is “antibiotic use” and the random effect is one of eight specific symptoms.  
Variance inflation factors were checked and determined there was no multicollinearity 
between the independent variables (specific patient symptoms).  Multicollinearity arises 
when independent variables are too strongly correlated, which results in inflated standard 
	 	
	 55 
errors, which yield artificially high P-values (Upton & Cook, 2014).  None of the patients 
displayed symptoms of hematochezia, so no conclusions were made about that symptom.  
There was not sufficient evidence to suggest that a significant association between any of 
the remaining seven symptoms and antibiotic treatment, p-value > 0.19, existed.  Table 7 
displays individual effect of a prescribed antibiotic upon admission and specified 
symptom effect.  
Table 7.  
Symptom effect on antibiotic treatment 
Effect F Value p-value 
Nausea vomiting  0.05 0.83 
Dehydration 0.16 0.69 
Abdominal Pain 1.55 0.22 
Distention Bloating 1.73 0.19 
Diarrhea/Steatorrhea 0.23 0.63 
Weight Loss 0.34 0.56 
Metabolic Acidosis 0.37 0.54 
 
 Is there a relationship between the presence of CLA-BSI and the patient’s 
age?  Mixed effects logistic regression was used to determine if there was a relationship 
between the patients age and the presence of CLA-BSI.  Again, a random effect was used 
to account for multiple admissions by the same patient.  
Analysis did not suggest a significant relationship between the presence of CLA-
BSI and the patient’s age, p-value 0.65.  Data was further analyzed to assess the 
frequencies of CLA-BSI in patients under the age of four (n=10) and over the age of four 
(n=18).  There was not sufficient evidence to suggest there is a significant relationship 
between a patient being under or over the age of four and CLA-BSI, p-value 0.85.  
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 Are there differences in the number of symptoms between patients who are 
treated with antibiotics for SBBO and those who are not?  Descriptive statistics, 
frequencies and a mixed effects negative binomial regression was used to determine if 
there was a relationship between the number of symptoms present and the use of 
antibiotic treatment for SBBO.  Two patients were removed from the analysis as they 
were already taking antibiotics upon admission (n=144).  The range of symptoms 
reported was 0-5 symptoms per patient.  The number of symptoms in those who received 
antibiotics (M = 1.49, SD = 1.49, R = 0-5) was similar to the number of symptoms in 
those who did not receive antibiotics (M = 1.22, SD = 1.37, R = 0-5).  Based on a p-value 
of 0.50, there is not sufficient evidence to suggest there is a significant association 
between the number of symptoms and antibiotic treatment.  Specific combinations of 
symptoms were not tested, only the number of symptoms was considered.  Table 8 shows 
the relationship between the number of symptoms present and treatment for SBBO with 
antibiotics.  
Table 8.  
Relationship between antibiotic use and number of symptoms   
Use of antibiotic for 
SBBO 
Number of SBBO symptoms 
0          1          2          3          4          5     
Total 
patients 
  
 
15        12         7         4          6           1                    45  
33%     27%     16%    9%       13%      2%                 
 
 
 
38        30         12       11        6           2                    99 
38%     30%      12%   11%     6%       2%           
 
53         42         19       15        12        3                  144        
Yes 
Frequency 
Row percent 
 
No 
Frequency 
Row percent 
 
Total                                         
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Do patients being treated with antibiotics for SBBO have a shorter length of 
stay than those who are not receiving antibiotics?  A shared frailty Cox proportional 
hazards model was used to determine if patients who are treated with antibiotics for 
SBBO have a shorter length of stay than those who do not receive antibiotics.  Frailty 
models are subject-specific survival models with at least one random effect that corrects 
for bias in fixed effect parameter estimates and estimates of standard errors due to 
unobserved correlation between observations (Amrhein, 2014).  The length of stay for 
patients who received antibiotics for SBBO ranged from 1-152 days (M = 18.8, SD = 
36.32), while those who did not receive antibiotics stayed between 0-108 days (M = 11.6, 
SD = 20.53).  Data did not suggest a significant association between antibiotic use and 
length of stay in the hospital, p-value 0.13.  However, clinical significance is noted in that 
those patients who did not receive antibiotics resulted in an average 7.2 fewer 
hospitalization days.   
Do patients being treated with antibiotics for SBBO have a higher rate of 
resolution of symptoms than those who are not receiving antibiotics?  Whether the 
symptoms resolved for patients treated with antibiotics could only be established based 
on the chart review, however documentation was insufficient and no statistical conclusion 
could be made.  Only 10 cases or four unique patients from the chart review documented 
whether there was a resolution of symptoms.  It was hypothesized that those who 
received antibiotics would have a higher rate of symptom resolution than those who did 
not receive antibiotics.  Unfortunately, there was not enough data to make a statistical 
conclusion to support that hypothesis.  Interestingly, the data did show that those who did 
not receive antibiotics actually had a shorter length of stay by 7.2 hospital days.  
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However, comparison of their illnesses were not made.  Actual counts of the visits with 
known resolutions of symptoms based on antibiotic status is provided in Table 9.  
Table 9.  
Resolution of symptoms by antibiotic status 
Antibiotic Resolution of Symptoms 
 
 Yes No Total 
Yes 4/44% 5/56% 9 
No  1/100% 0 1 
Total 5 5 10 
 
  How many of the reviewed patients (in terms of visits) were prescribed 
antibiotics who did not meet the criteria for risk factors for SBBO or have 
signs/symptoms of SBBO?  Of these, how many antibiotics exposed days were there?  
What was the costs of the antibiotics?  Every patient reviewed had at least one 
anatomical, functional, or multi-factorial risk factor.  However, there were 15 visits 
representing 11 unique patients who did not have documented signs or symptoms of 
SBBO but were prescribed antibiotics.  This represents 342 antibiotic exposed days and 
more than $24,000 in medication costs.  Of the 41 patient visits that were exposed to 
antibiotics, most of them were a continuation of a home medication (n=27) prescribed as 
a recurring medication based on prior clinical suspicion.  Twelve cases were prescribed 
antibiotics based on clinical suspicion during that visit.  Only 2 patients underwent more 
extensive testing such as duodenal aspirate during their visit.  
 Of the reviewed patients (in terms of visits) who received antibiotic treatment 
for SBBO, how many developed a CLA-BSI within three months?  What SBBO 
antibiotic was used?  What organism/s grew?  Did the central venous catheter have 
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to be removed?  If the central venous catheter was removed, how many additional 
days did the patient stay in the hospital?  Of those who were prescribed antibiotics for 
SBBO, seven admission visits representing five unique patients acquired a CLA-BSI 
within three months of SBBO treatment.  Metronidazole was prescribed in five of the 
seven cases, Vancomycin was used once, and a combination of amoxicillin-clavulanic 
acid and sulfamethoxazole/trimethoprim was used once.  The most common offending 
organism was a Staph species (n=6).  In two of the infections, more than one organism 
was isolated including one Staph species.  The central venous catheter had to be removed 
in six of those seven incidents.  This resulted in an additional 106 hospital days with an 
additional $265,000 in medical charges based on an average of $2,500 per inpatient day 
for non-profit hospitals in Ohio.  Table 10 summarizes CLA-BSI following antibiotic 
exposure for SBBO.  
Table 10.  
Summary of CLA-BSI following antibiotic exposure for SBBO 
Type of Antibiotic Type of 
Organism 
Second 
Organism 
Central 
Line 
Removed 
Additional 
Days at 
Hospital  
Metronidazole 
Metronidazole 
Metronidazole 
Vancomycin 
Metronidazole 
Metronidazole 
Amoxicillin-Clavulanic and 
sulfamethoxazole/trimethoprim 
Staph 
Staph 
Staph 
Staph 
Staph 
Other 
Staph 
- 
Other 
Other 
- 
- 
- 
- 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
19 
38 
18 
8 
- 
6 
7 
 
Do patients with certain anatomic risk factors who are treated with 
antibiotics for SBBO have CLA-BSI more frequently than patients with other 
anatomic risk factors?  A mixed effects multiple logistic regression was used to 
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determine the relationship between the presence of certain risk factors and the incidence 
of CLA-BSI.  Variance inflation factors were checked and determined there was no 
multicollinearity between the independent variables (anatomical risk factors).  There is 
strong evidence to suggest a significant relationship between “presence of an ostomy” 
and developing a CLA-BSI, OR = 4.976, 95% CI [1.467, 16.879], p=0.01.  This finding 
suggests that patients with an ostomy have 5 times the odds of developing a CLA-BSI 
then a patient without an ostomy.  Findings from the analysis did not suggest a 
statistically significant relationship between any of the other anatomical risk factors and 
the incidence of CLA-BSI.  Table 11 displays the results of the mixed effects of 
anatomical factors and the presence of a CLA-BSI.  
Table 11.  
Anatomical factors effect on CLA-BSI 
Effect F-value p-value 
Short Bowel Syndrome 0.02 0.88 
Abdominal Wall Defect 0.05 0.83 
Small Bowel Atresia 1.32 0.26 
Necrotizing Enterocolitis 0.68 0.41 
Malrotation 0.00 0.98 
Hirschsprung’s 0.95 0.33 
Ostomy 6.95 0.01* 
*statistically significant 
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V. DISCUSSION 
 Literature regarding antibiotic therapy as a treatment for SBBO in pediatrics 
patients with short bowel syndrome is limited.  The findings highlighted in this evidence-
based project were not always statistically significant.  The findings are clinically 
relevant and will contribute to the scientific community.  The findings from this project 
have paved the way for process improvement including standardization of care.   
 Findings from this evidence-based project were expected to determine the 
effectiveness of antibiotics as a treatment in SBBO for pediatric patients with short bowel 
syndrome.  Unfortunately, the effect of antibiotic therapy in this population was 
inconclusive due to limited clinical documentation.  The data that was collected showed 
that patients had symptom resolution more frequently without antibiotic therapy (n=5) 
than with antibiotic therapy (n=4), but statistical conclusions could not be drawn due to 
limited data.  While it is noted that those who did not receive antibiotics also had a 
shorter length of stay by 7.2 days, it is important to remember that patients were not 
matched for illness severity and those with a longer length of stay may have had a more 
complicated presentation. 
 As supported by the literature, incidence of SBBO in this group is challenging to 
report.  DiBaise et al. (2006) state that little is actually known about the prevalence of 
SBBO due to diagnostic barriers.  The literature speaks to the difficulty in diagnosing 
SBBO due to the invasive nature of the diagnostic methods, therefore it is often 
diagnosed presumptively based on clinical symptoms (DiBaise et al., 2006; Malik et al., 
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2011; Xie, 2011).  Data from this project shows that in most cases antibiotics were 
prescribed based on prior clinical suspicion from the outpatient provider at some time 
before the hospitalization.  Far fewer cases were prescribed antibiotics based on clinical 
suspicion during the visit.  Only two patients had confirmatory diagnostic testing with 
duodenal aspiration, which the literature suggests is the gold standard testing method 
(DiBaise et al., 2006; Sieczkowska et al., 2016; Xie, 2011). 
 The data did reveal inconsistencies in prescribing practices under these clinical 
circumstances.  The chart review of 146 admission visits showed that antibiotics were 
prescribed or continued during an admission 47 times for SBBO.  In five of those cases, 
the patient received two antibiotics at the same time.  The presence of any one risk factor, 
any one symptom (p > 0.19), or the presence of multiple symptoms (p = 0.50) did not 
directly correspond to the prescribing of antibiotics.  The inconsistencies in prescribing 
practices were noted in terms of patient identification and antibiotic selection.   
 The literature supports the use of antibiotics, specifically metronidazole, 
nitazoxanide, rifaximin, and sulfamethoxazole/trimethoprim, to decrease the symptoms 
associated with SBBO (Attar et al., 1999; Cole & Kocoshis, 2013; Di Stefano et al., 
2005; Lauritano et al., 2005; Lauritano et al., 2009).  Other treatment modalities such as 
bowel flushing, probiotics and prokinetics were reported, but without sufficient data to 
support their efficiency.  Consistent with the literature, data showed that patients at 
CCHMC are prescribed metronidazole 65% of the time in cases of suspected SBBO 
followed by nitazoxanide, rifaximin, and sulfamethoxazole/trimethoprim.  Non-
pharmacological treatment modalities were not reported.  Despite the literature and 
current practices, experts in the field are now moving away from prophylactic use of 
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antibiotics.  The risk of repeated or inappropriate antibiotic exposure may outweigh the 
benefits leading to disruption of the fecal microbiome and antibiotic resistant bacteria.   
 A significant correlation was found between the presence of an ostomy and 
incidence of CLA-BSI (p = 0.01).  Incidence of CLA-BSI was not otherwise statistically 
significant in relation to patient age (p = 0.65) or any other single risk factor.  Data from 
this project will be used to shape the way patients with ostomies and central venous 
catheters are cared for moving forward at CCHMC. 
  There were several limitations to this project.  The lack of relevant pediatric 
literature was a barrier during the literature review phase.  As most of the 
recommendations for diagnosis and treatment are extrapolated from adult literature, such 
had to be reviewed and considered for this project.  The project was limited by the small 
sample size.  Expanding the chart review to a two-year period would likely have 
produced more patients.  The lack of documentation regarding symptom resolution 
prohibited the analysis of this as an outcomes measure.  Expanding the inclusion criteria 
to include outpatient visits, may have revealed more succinct consistency in diagnosing 
and prescribing practices.  The outpatient providers are smaller in number compared to 
the number of inpatient providers and are considered content experts with medical 
practices focused solely on this population.  
 Despite the limitations, the project had many strengths.  This project helped bring 
to light the inconsistences in prescribing practices for SBBO at CCHMC.  Identification 
of such inconsistencies revealed an excess of $24,000 in medical costs associated with 
unjustified antibiotic prescribing.  Data also revealed an additional 106 hospital days and 
$265,000 in inpatient hospital days associated with CLA-BSI requiring central venous 
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catheter removal following a course of antibiotics for presumed SBBO.  The findings 
from this evidence-based project have supported the development and future 
implementation of the BESt document.  The findings support inconsistencies in patient 
identification based on risk factors and symptoms of SBBO as well as inconsistencies in 
prescribing practices.  This lack of clinical consistency strengthens the need for 
standardization of care. 
 This evidence-based project has implications for use beyond the focus of this 
project.  Based on the preliminary data shared, the antibiotic stewardship team at 
CCHMC is interested in pursuing new clinical research aimed at DNA mapping for 
future duodenal aspirates in pediatric patients with short bowel syndrome.  DNA 
mapping of duodenal aspirates will assist providers in targeted antibiotic selection based 
on real time patient results.  Over a period of time, enough samples may be collected that 
will help guide antibiotic therapy preferences in general moving forward.  At the time 
DNA mapping is adopted, the BESt may need to be revised depending on the findings.   
 An additional implication for practice relates to central line care for patients with 
an ostomy.  CLA-BSI are tracked at CCHMC by medical unit and staff nurses receive 
feedback relative to their unit performance.  Based on data presented herein, there is now 
great interest from nursing to take a closer look at central venous catheter care protocols 
and modifying them for patients with ostomies with the goal to reduce future CLA-BSI in 
these patients.  
 The absence of provider documentation was an incidental finding and a large 
barrier to the project.  Moving forward, there are plans to develop a prescribing order set 
for SBBO antibiotics that will require providers to document the patient’s risk factors and 
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presenting signs and symptoms.  Activation of the order set can be linked to a 
documentation reminder one week later that requires providers to answer to the resolution 
of symptoms.  These process improvements will improve the understanding the efficacy 
of antibiotic treatment for pediatric patients with short bowel syndrome and SBBO.  
 In alignment with The Essentials for Doctoral Education for Advanced Nursing 
Practice Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based 
Practice, the DNP student is prepared to disseminate findings from evidence-based 
practice and research to improve healthcare outcomes (Nursing, 2006).  The ultimate goal 
for this project is peer reviewed publication in a medical or nursing journal.  However, 
the completion of this goal will fall outside the timeframe of the academic plan of study 
due to delays with IRB determination.  Publishing in a peer reviewed journal is no small 
feat, but successful submission and acceptance of a manuscript garners respect for the 
published work and contributes to the scientific community.  Evidence-based prescribing 
recommendations have been drafted under the mentorship of gastroenterology and 
infectious disease experts and will be proposed in the form of a BESt document for use 
throughout the organization at CCHMC.   
 Patients with short bowel syndrome are complex and have many medical needs 
making their care complicated and sometimes confusing.  One condition that can be 
detrimental to their health is SBBO.  SBBO can be difficult to identify and even more 
difficult to treat without pediatric clinical trials to support decision making.  Based on a 
one-year retrospective chart review, in-depth statistical analysis, and content expert 
opinions, a BESt document has been drafted for implementation at CCHMC providing a 
framework from which to make clinical decisions.  Patients with SBBO may benefit from 
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antibiotic therapy and deserve that opportunity when indicated, but equally as valuable is 
avoiding antibiotic exposure in patients who do not have a clear indication for treatment.  
It is a providers’ responsibility to understand the difference to the best of their ability and 
prescribe accordingly, this project will facilitate that for pediatric patients with short 
bowel syndrome.  
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Appendix A 
Database Search/Keywords 
Keyword(s), subject, 
headings, MeSH terms 
Database Limits 
applied 
Number of hits 
   Listed Reviewed Used 
small bowel bacterial 
overgrowth, small intestine 
bacterial overgrowth, SBBO, 
SIBO, blind loop syndrome, 
antibiotic, prophylactic 
antibiotic, antibacterial 
agents, or anti-infective 
agents 
Cochrane 
Database 
for 
Systematic 
Reviews 
2006 to 
present, 
English 
language 
0 
systematic 
review 
 
1 meta-
analysis 
 
41 trials 
7 2 
"Intestine, 
Small/microbiology"[MAJR] 
AND "humans"[MeSH 
Terms]) AND ("Anti-
Bacterial Agents "[MeSH] 
AND "humans"[MeSH 
Terms]) AND 
"humans"[MeSH Terms] 
AND 
PubMed 2006 to 
present, 
English 
language 
59 17 9 
 
Small bowel bacterial 
overgrowth AND antibiotics 
CINAHL 2006 to 
present, 
English 
language 
12 2 2 
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Appendix B 
LEGEND Table of Evidence Levels 
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TABLE OF EVIDENCE LEVELS: Levels of Individual Studies by Domain, Study Design, & Quality 
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DOMAIN OF 
CLINICAL QUESTION 
Intervention 
1a* 
1b* 
 
2a 
2b 
3a 
3b 
 
4a 
4b 
3a 
3b 
4a 
4b 
4a 
4b 
4a 
4b 
4a 
4b 
4a 
4b 
4a 
4b 
2a/2b 
3a/3b 
4a/4b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
Treatment, Therapy, 
Prevention, Harm, 
Quality Improvement 
Diagnosis / Assessment 
1a 
1b 
  
2a 
2b 
2a 
2b 
 
3a 
3b 
4a 
4b 
  4a 
4b 
4a 
4b 
 
2a/2b 
3a/3b 
4a/4b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
Prognosis 
1a 
1b 
     2a 
2b 
3a 
3b 
4a 
4b 
 4a 
4b 
4a 
4b 
 
2/3/4 
a/b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
Etiology / Risk Factors 
1a 
1b 
 
2a 
2b 
3a 
3b 
  3a 
3b 
4a 
4b 
4a 
4b 
 
4a 
4b 
4a 
4b 
 
2/3/4 
a/b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
Incidence 
1a 
1b 
     
2a 
2b 
3a 
3b 
   
4a 
4b 
   
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
Prevalence 
1a 
1b 
       
2a 
2b 
 
3a 
3b 
4a 
4b 
   
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
Meaning / KAB+  
1a 
1b 
   
2a 
2b 
       2/3/4 
a/b  
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5 
 * a = good quality study       b = lesser quality study 
 + CCT = Controlled Clinical Trial       KAB = Knowledge, Attitudes, and Beliefs       RCT = Randomized Controlled Trial 
 
Shaded boxes indicate study design may not be appropriate or commonly used for the domain of the clinical question. 
 
Development for this table is based on:  
1. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from HUhttp://www.cebm.net/index.aspx?o=1025UH. 
2. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005. 
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Appendix C 
Example LEGEND Critical Appraisal Form [Expert Opinion] 
	
	
LEGEND:  Evidence Appraisal of a Single Study 
All Domains 
Expert Opinion 
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Project/Topic of your Clinical Question:  
Reviewer:  Today’s Date:  Final Evidence Level:  
Article Title:  
Year:  First Author:   Journal:  
 
 
 
Do the aim/purpose/objectives assist in answering your clinical question?   Yes    No    Unknown 
• Aim/Purpose/Objectives: 
 
 
 
 
 
 
When reading the bolded questions, consider the bulleted questions to help answer the main question. 
If you are uncertain of your skills in evidence evaluation, please consult a local evidence expert for assistance: 
CCHMC Evidence Experts: http://groups/ce/NewEBC/EBDMHelp.htm 
Unfamiliar terms can be found in the LEGEND Glossary:  http://groups/ce/NewEBC/EBCFiles/GLOSSARY-EBDM.pdf 
 
 
BASIC ELEMENTS OF AN EXPERT OPINION / REVIEW ARTICLE 
 
1. Is the author a known expert in the field being studied?     Yes    No    Unknown 
• What are the author’s credentials? 
Comments:   
 
 
 
2. Does the author have a known bias?        Yes    No    Unknown 
Comments:   
 
 
 
3. Is the patient population, problem, or issue clearly described?    Yes    No    Unknown 
Comments:   
 
 
 
4. Is the literature search clearly described?        Yes    No    Unknown 
Comments:   
 
 
 
5. Is the date range of the cited literature appropriate and current?    Yes    No    Unknown 
Comments:   
 
 
 
6. What types of research are cited (e.g., animal model, basic science, clinical studies)? 
Comments:   
 
 
 
7. Is more than one point of view explained, reported, or referenced?    Yes    No    Unknown 
Comments:   
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LEGEND:  Evidence Appraisal of a Single Study 
All Domains 
Expert Opinion 
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8. Were any conclusions clearly presented in the article?      Yes    No    Unknown 
• If applicable, were any adverse events clearly described? 
Comments:   
 
 
 
 
9. Was there freedom from conflict of interest?      Yes    No    Unknown 
• Sponsor/Funding Agency or Authors 
Comments:   
 
 
 
 
 
APPLICABILITY: CAN I APPLY THIS EXPERT OPINION / GENERAL REVIEW INFORMATION? 
 
10. Can the results be applied to my population of interest?     Yes    No    Unknown 
• Is the setting described in the article applicable to my population of interest? 
• Do the patient outcomes apply to my population or question of interest? 
• Were the patients in this article similar to my population of interest? 
Comments:   
 
 
 
 
11. Are my patient’s and family’s values and preferences satisfied by the knowledge 
gained from this article (such as outcomes considered)?      Yes    No    Unknown 
Comments:   
 
 
 
 
12. Would you include this article in development of a care recommendation?   Yes    No    Unknown 
Comments:   
 
 
 
 
 
 
 
 
 
ADDITIONAL COMMENTS OR CONCLUSIONS (“TAKE-HOME POINTS”):   
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LEGEND:  Evidence Appraisal of a Single Study 
All Domains 
Expert Opinion 
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QUALITY LEVEL / EVIDENCE LEVEL 
 
• Consider each “No” answer and the degree to which this limitation is a threat to the validity of the results, then check the 
appropriate box to assign the level of quality for this study/article. 
• Consider an “Unknown” answer to one or more questions as a similar limitation to answering “No,” if the information is not 
available in the article. 
 
 
 
THE EVIDENCE LEVEL IS:     Good Quality Expert Opinion / General Review [5a] 
   Lesser Quality Expert Opinion/General Review [5b] 
 
   Not Applicable 
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All Domains 
1a 
1b           
4a 
4b  
2/3/4 
a/b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 5 
  + RCT = Randomized Controlled Trial; CCT = Controlled Clinical Trial 
 
 
 
Development for this appraisal form is based on: 
1. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005. 
2. Guyatt, G.; Rennie, D.; Evidence-Based Medicine Working Group.; and American Medical Association.: Users' guides to the medical literature : a manual for evidence-
based clinical practice. Users' guides to the medical literature : a manual for evidence-based clinical practice: "JAMA & archives journals." Chicago, IL, 2002 
3. Melnyk, B. M. and E. Fineout-Overholt (2005). Evidence-based practice in nursing & healthcare: a guide to best practice. Philadelphia, Lippincott Williams & Wilkins. 
4. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from http://www.cebm.net/index.aspx?o=1025. 
5. Local Consensus 
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Appendix C-continued 
Example LEGEND Critical Appraisal Form [Systematic Review/Meta-analysis] 
 
 
LEGEND:  Evidence Appraisal of a Single Study 
Intervention 
Systematic Review / Meta-Analysis 
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Project/Topic of your Clinical Question:  
Reviewer:  Today’s Date:  Final Evidence Level:  
Article Title:  
Year:  First Author:   Journal:  
 
 
 
Do the study aim/purpose/objectives and inclusion/exclusion criteria assist in answering your clinical question? 
    Yes    No    Unknown 
• Study Aim/Purpose/Objectives: 
 
 
• Inclusion Criteria: 
 
 
• Exclusion Criteria: 
 
 
 
 
 
When reading the bolded questions, consider the bulleted questions to help answer the main question. 
If you are uncertain of your skills in evidence evaluation, please consult a local evidence expert for assistance: 
CCHMC Evidence Experts: http://groups/ce/NewEBC/EBDMHelp.htm 
Unfamiliar terms can be found in the LEGEND Glossary:  http://groups/ce/NewEBC/EBCFiles/GLOSSARY-EBDM.pdf 
 
 
VALIDITY:       ARE THE RESULTS OF THE SYSTEMATIC REVIEW / META–ANALYSIS VALID OR CREDIBLE? 
 
1. Did the overview address a focused clinical question?      Yes    No    Unknown 
Comments:   
 
 
2. Was the search for relevant studies detailed and exhaustive?     Yes    No    Unknown 
• Was it unlikely that important, relevant studies were missed? 
Comments:   
 
 
3. Did the systematic review use RCTs?        Yes    No    Unknown 
• Were the criteria used to select articles for inclusion appropriate? 
• Was the assignment of patients to treatments randomized? 
Comments:   
 
 
4. Were the included studies appraised and assigned a high level of quality?   Yes    No    Unknown 
Comments:   
 
 
5. Were the methods consistent from study to study?      Yes    No    Unknown 
• Were populations among the included studies comparable and appropriate? 
• Were the outcomes, interventions, and exposures measured in the same way  
in the groups being compared? 
Comments:   
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LEGEND:  Evidence Appraisal of a Single Study 
Intervention 
Systematic Review / Meta-Analysis 
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6. Was there freedom from conflict of interest?      Yes    No    Unknown 
• Sponsor/Funding Agency or Investigators 
Comments:   
 
 
 
RELIABILITY:       ARE THESE VALID STUDY RESULTS IMPORTANT? 
 
7. What were the main results of the systematic review/meta-analysis? (e.g., Helpful data: Page #, Table #, Figures, Graphs) 
 
 
 
• What was the effect size?  (How large was the treatment effect?) 
 
 
 
• What were the measures of statistical uncertainty (e.g., precision)? 
(Were the results presented with Confidence Intervals or Standard Deviations?) 
 
 
 
8. Were the results statistically significant?       Yes    No    Unknown 
Comments:   
 
 
 
9. Were the results clinically significant?       Yes    No    Unknown 
• If potential confounders were identified, were they discussed in relationship 
to the results? 
Comments:   
 
 
 
10. Were adverse events discussed?        Yes    No    Unknown 
Comments:   
 
 
 
 
APPLICABILITY:       CAN I APPLY THESE VALID, IMPORTANT STUDY RESULTS TO TREATING MY PATIENTS? 
 
11. Can the results be applied to my population of interest?     Yes    No    Unknown 
• Is the treatment feasible in my care setting? 
• Do the patient outcomes apply to my population or question of interest? 
• Are the likely benefits worth the potential harm and costs?  
• Are the patients in this study similar to my population of interest?  
Comments:   
 
 
12. Are my patient’s and family’s values and preferences satisfied by the treatment 
and its consequences?         Yes    No    Unknown 
Comments:   
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LEGEND:  Evidence Appraisal of a Single Study 
Intervention 
Systematic Review / Meta-Analysis 
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13. Would you include this study/article in development of a care recommendation?  Yes    No    Unknown 
Comments:   
 
 
 
 
 
 
ADDITIONAL COMMENTS OR CONCLUSIONS (“TAKE-HOME POINTS”):   
 
 
 
 
 
 
 
QUALITY LEVEL / EVIDENCE LEVEL 
 
• Consider each “No” answer and the degree to which this limitation is a threat to the validity of the results, then check the 
appropriate box to assign the level of quality for this study/article. 
• Consider an “Unknown” answer to one or more questions as a similar limitation to answering “No,” if the information is not 
available in the article 
 
 
 
THE EVIDENCE LEVEL IS:      Good Quality Systematic Review  [1a] 
   Lesser Quality Systematic Review  [1b] 
 
   Not Valid, Reliable, or Applicable 
 
 
 
Table of Evidence Levels 
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Intervention 
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4b 
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3b 
4a 
4b 
4a 
4b 
4a 
4b 
4a 
4b 
4a 
4b 
4a 
4b 
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a/b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 
5a 
5b 5 
Treatment, Therapy, 
Prevention, Harm, 
Quality Improvement 
+ 
RCT = Randomized Controlled Trial; CCT = Controlled Clinical Trial 
 
 
 
Development for this appraisal form is based on: 
1. Guyatt, G.; Rennie, D.; Evidence-Based Medicine Working Group.; and American Medical Association.: Users' guides to the medical literature : a manual for evidence-
based clinical practice. Users' guides to the medical literature : a manual for evidence-based clinical practice: "JAMA & archives journals." Chicago, IL, 2002 
2. Melnyk, B. M. and E. Fineout-Overholt (2005). Evidence-based practice in nursing & healthcare : a guide to best practice. Philadelphia, Lippincott Williams & Wilkins. 
3. Lohr, K. N. and T. S. Carey (1999). "Assessing "best evidence": issues in grading the quality of studies for systematic reviews." Joint Commission Journal on Quality 
Improvement 25(9): 470-9. 
4. Fineout-Overholt, E. and L. Johnston (2005). "Teaching EBP: asking searchable, answerable clinical questions." Worldviews Evid Based Nurs 2(3): 157-60. 
5. Jerosch-Herold, C. (2005). "An evidence-based approach to choosing outcome measures: a checklist for the critical appraisal of validity, reliability and responsiveness 
studies." British Journal of Occupational Therapy 68(8): 347-53. 
6. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from http://www.cebm.net/index.aspx?o=1025. 
7. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005. 
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Appendix D 
LEGEND Grading the Body of Evidence 
	
 
LEGEND 
Let Evidence Guide Every New Decision 
Grading the Body of Evidence 
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Grade Method 
High 
Step 1 
(see worksheet to 
summarize the body of 
evidence) 
NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
1 1a NA 
2+ 1a or 2a Yes 
5+ 1a, 2a, or 3a Yes 
5+ 1a, 1b, 2a, or 2b Yes 
Step 2 
(if the studies didn’t fit 
neatly into a box in 
step 1) 
• multiple studies, unless large effect and very clinically important 
• strong designs for answering the question addressed 
• clinically important and consistent results with minor exceptions at most 
• free of any significant doubts about validity       (generalizability, bias, design flaws) 
• adequate statistical power       (including studies showing no difference) 
Sufficient number of 
high quality studies 
with consistent* 
results 
Confirmation Step Further research is unlikely to change our confidence in the answer to the clinical question. 
Moderate 
Step 1 
(see worksheet to 
summarize the body of 
evidence) 
NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
1 2a NA 
3+ 1, 2, 3; a or b Yes 
5+ 1, 2, 3, 4; a or b Yes 
Step 2  
(if the studies didn’t fit 
neatly into a box in 
step 1) 
Either 
• multiple studies 
• strong designs for answering the question addressed 
• some uncertainty due to either 
• validity threats (generalizability, bias, design flaws or adequacy of statistical power) or 
• inconsistency 
Or 
• multiple studies 
• weaker designs for answering the question addressed 
• consistent results with minor exceptions at most 
A single well-done 
study or 
Multiple studies of 
lesser quality or with 
some uncertainty 
Confirmation Step Further research is likely to have an important impact on our confidence in the precision of the answer 
to the clinical question, and may even change the answer itself. 
Low 
Step 1 
(see worksheet to 
summarize the body of 
evidence) 
NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
1+ Insufficient quality to meet 
Moderate criteria above Yes 
Local opinion or  
Published non-research articles 5 Yes 
Step 2 
(if the studies didn’t fit 
neatly into a box in 
step 1) 
• health professional opinion is the only relevant published information 
• local consensus is clear 
• uncertainty due to either 
• validity threats (generalizability, bias, design flaws or adequacy of statistical power) or 
• inconsistency 
Studies with 
insufficient quality 
including case 
reports, case studies, 
general reviews, and 
local consensus 
Confirmation Step There is published and/or local consensus, but little or no research, to answer the clinical question. 
Further research is very likely to have an important impact on the answer. 
Grade 
Not Assignable 
Step 1 NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
 0+  Any evidence level No 
Local opinion 5 No 
Step 2  
(if the studies didn’t fit 
neatly into a box in 
step 1) 
• studies have not been done, or 
• published studies are seriously flawed, and/or 
• published studies give inconsistent results 
Insufficient design or 
execution, too few 
studies, inconsistent 
results, and lack of 
consensus 
Confirmation Step There is insufficient evidence and lack of consensus to answer the clinical question. 
*Note:  When there is both high and low quality evidence and the results are inconsistent: 
• Disregard lower quality evidence if the lower quality evidence is inconsistent with all higher quality evidence. 
• Avoid disregarding lower quality evidence when inconsistency is at multiple quality levels, because bias could be introduced when determining which evidence to disregard. 
 
Some of the concepts for this development are based on: Atkins et al: Grading quality of evidence and strength of recommendations. BMJ, 328(7454): 1490, 2004; 
Briss et al: Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med, 18(1 Suppl): 35-43, 2000; & 
Greer et al: A practical approach to evidence grading. Jt Comm J Qual Improv, 26(12): 700-12, 2000. 
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LEGEND 
Let Evidence Guide Every New Decision 
Judging the Strength of a Recommendation 
 
 
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.                     June 11, 2012 
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library | 
Occupational Therapy & Physical Therapy | Hospital Medicine                www.cincinnatichildrens.org/evidence 
Project Title:       Date:       
In determining the strength of a recommendation, the development group makes a considered judgment. 
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience, 
and other dimensions.  The development group will consider what the relative weight each dimension listed below 
contributes when determining the strength of a recommendation. 
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates 
support for a stronger recommendation, complete one of the sentences below to judge the strength of this 
recommendation. 
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
 It is strongly recommended that… 
 It is recommended that… 
 There is insufficient evidence and a lack of 
consensus to make a recommendation on… 
      
 
Dimensions 
1. Grade of the Body of Evidence  High grade evidence  Moderate grade 
evidence 
 Low grade evidence 
2. Safety / Harm  Has minimal adverse 
effects 
 Has moderate adverse 
effects 
 Has serious adverse 
effects 
3. Benefit to target population 
 (e.g., health benefit to patient) 
 Has significant benefit  Has moderate benefit  Has minimal benefit 
4. Burden on population to adhere 
to recommendation 
(e.g., cost, hassle, discomfort, pain, 
motivation, ability to adhere, time) 
 Low burden of 
adherence 
 Unable to determine 
burden of adherence 
 High burden of 
adherence 
5. Cost-effectiveness to healthcare 
system  
(e.g., balance of cost/savings of 
resources, staff time, supplies based 
on published studies/onsite analysis) 
 Cost-effective to 
healthcare system 
 Inconclusive economic 
effects 
 Not cost-effective to 
healthcare system 
6. Directness 
(the extent to which the body of 
evidence directly answers the clinical 
question [population/problem, 
intervention, comparison, outcome]) 
 Evidence directly 
relates to 
recommendation for 
this target population. 
 There is some concern 
about the directness of 
evidence as it relates 
to the recommen-
dation for this target 
population. 
 Evidence only 
indirectly relates to 
recommendation for 
this target popula-
tion. 
7. Impact on morbidity, mortality, 
or quality of life 
 High impact on 
morbidity, mortality, 
or quality of life 
 Medium impact on 
morbidity, mortality, 
or quality of life 
 Low impact on 
morbidity, mortality, 
or quality of life 
 
Some of the concepts for this development based on: 
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians 
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6, 
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005. 
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EBDM Evidence Summary Table 
CHARACTERISTICS |  RESULTS  |  CONCLUSIONS  |  EVIDENCE LEVELS 
 
Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved. 
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm 
James M. Anderson Center for Health Systems Excellence 
TITLE, IF APPLICABLE OR IF MULTIPLE TABLES 
Study Citation 
Study Type N 
Sample Size 
Population 
(Setting, Patients) 
Intervention / Comparison Groups Outcomes 
Significant Results 
Including estimates with associated precision (e.g., Odds Ratios or NNT with Confidence Intervals) 
Conclusions  
Including Limitations, Gaps, Applicability, or other Notes 
Evidence 
Level 
Reed, 2014 Expert opinion NA Pediatrics with SBBO and short bowel 
syndrome 
NA x Prompt diagnosis and 
treatment of SBBO can 
improve the nutrition status of 
pediatric pts with SBS 
x NA x Amox-clav acid 10 mg/kg/dose twice daily 
x Ciprofloxacin 10-20 mg/kg/dose twice daily 
x Clindamycin 10-30 mg/kg/d divided three times per day 
x Doxycycline 100 mg twice daily (only >8 yr old) 
x Metronidazole 10 mg/kg/dose twice daily 
x Neomycin 50 mg/kg/d divided every 6 hours 
x Tetracycline 25-50 mg/kg/d divided every 6 hours (only >8yr old) 
x Vancomycin 10 mg/kg/dose every 6 hours 
5a 
DiBaise, 2006 Expert opinion NA Patients with SBBO and short bowel 
syndrome 
NA x Recommendations on the basis 
of clinical experience is 
necessary 
x NA x May require trial and error approach to antibiotic therapy. 
Antimicrobial therapy should provide coverage for both aerobic and 
anaerobic organisms, monotherapy against anaerobes should be 
avoided 
5a 
Malik, 2011 Expert opinion NA Pediatrics with SBBO and intestinal failure NA x For cases in which a firm dx 
cannot be made, but clinical 
symptoms favor SBBO – 
empiric antibiotics may be a 
more cautious approach 
x NA x Trimethoprim/sulfa 2-10 mg/kg/dose twice daily 
x Metronidazole 10 mg/kg/dose twice daily 
x Amox-clav acid 15 mg/kg/dose twice daily 
x Rifaxamin 10-15 mg/kg/dose twice daily 
x Tetracycline 10-15 mg/kg/dose twice daily (only >8 yr old) 
x Ciprofloxacin 10-10 mg/kg/dose twice daily 
x Gentamicin 5 mg/kg/dose twice daily 
x Neomycin 2.5 mg/kg/dose four times daily 
5a 
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Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved. 
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm 
James M. Anderson Center for Health Systems Excellence 
Cole, 2007 Expert opinion NA Pediatrics with SBBO and short bowel 
syndrome 
NA x Current understanding of 
bacterial in the intestines and 
issues related to SBBO 
x NA x Antibiotics: Metronidazole, Bactrim, Augmentin, Rifaximin, Cipro, 
Chloramphenicol, Doxycycline, Neomycin, and Norfloxacin 
x Probiotics: Lactobacillus species, Bifidobacterium species, Bacillus 
cereus, Enterococcus faecalis, E coli Nissle 1917, Saccharomyces 
boulardii, Saccaromyces cerevisiae, and Streptococcus thermophiles 
5a 
Quigley, 2006 Expert opinion NA Patients with SBBO NA x Management of patients with 
SBBO remains for the most 
part primarily empiric and 
comprises of antibiotic therapy 
and correction of nutritional 
deficiencies  
x NA x Antibiotics: Augmentin, Cipro, Chloramphenicol, Doxycycline, 
Metronidazole, Neomycin, Norfloxacin, Tetracycline, Bactrim, and 
Rifaximin 
5a 
Ching, 2007 Expert opinion NA Pediatrics with IF and SBBO NA x Short courses of oral 
antibiotics are the mainstay of 
therapy in SBBO 
x NA x Antibiotics: Amphotericin, Augmentin, Cipro, Clindamycin, Colistin, 
Doxycycline, Gentamicin, Metronidazole, Neomycin, Tetracycline, 
Tobramycin, Rifaximin, and Vancomycin 
5a 
Cole, 2013 Expert opinion NA Pediatrics with surgical short bowel and IF 
with SBBO 
NA x There are no large scale clinical 
trials evaluating the timing and 
effectiveness of antibiotics for 
SBBO 
x NA x Metronidazole is the most popular agent for eradicating 
anaerobes.  
x Nitazoxanide and rifaximin over obligate anaerobes effectively.  
x Bactrim, Gent, extended spectrum PCN, and cephalosporins 
cover putrefactive gram neg aerobes.  
x Augmentin effective against 90% of isolated species 
5a 
Shah, 2013 Meta-analysis 311 Pediatrics and adults with SBBO or SBBO 
symptoms 
Rifaximin vs placebo; rifaximin vs rifaximin plus additive; 
rifaxamin vs metronidazole; different rifaximin doses; 
metronidazole vs Cipro; neomycin vs placebo; rifaximin vs 
chlortetracycline 
x  
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Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved. 
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm 
James M. Anderson Center for Health Systems Excellence 
x Rifaximin overall breath test normalization rate of 49.5% (95% CI, CI 44.0 – 55.1) 
x Antibiotics were more effective than placebo with combined breath test 
normalization rate of 51.1% (95% CI 46.7-55.5) compared to 9.8% (95% Ci 4.6-17.8 
for placebo) 
x Meta-analysis of 4 studies favoured abx over placebo for breath test normalization 
with OR 2.55 (95% CI, 1.29-5.04) 
x Antibiotics appear to be more effective than placebo for breath test 
normalization in patients with SBBO symptoms; and breath test 
normalization may correlate with clinical response 
1a 
Sentongo, 2008 Expert opinion NA Pediatrics with SBBO NA x Definitive therapy in patients 
with recurring symptoms is 
correction of the predisposing 
factor; otherwise, 
management is mostly 
supportive 
x NA x Treatment of SBBO: 1) antibiotics and prophylaxis; 2) dietary 
approaches; 3) probiotics; 4) corrective or palliative surgery 
x Avoid antibiotics with poor activity against enteric anaerobes or oral 
aminoglycosides 
x Commonly used are metronidazole (bacteroides and anaerobic 
coverage), Bactrim (broad spectrum), and rifaximin (anaerobic coverage 
and non-absorbable) 
5a 
 
Sieczkowska, 2016 Expert opinion NA Pediatrics with SBBO NA x Further research is needed to 
determine the clinical impact 
of SBBO and establish 
diagnostic and therapeutic 
guidelines 
x NA x Treatment goals: correct underlying disease or defect, eliminate 
predisposing conditions, replete nutrition, modify microbiota with 
antibiotics or probiotics 
x One pediatric study of 20 children showed effective treatment with 14 
day course of Bactrim and metronidazole 
x Rifaximin studied in children with CAP and IBS 
x No official recommendations, too little data available 
x A non-absorbable antibiotic, like rifaximin, with a low incidence of side 
effects seems to be the best option for first-line treatment, especially in 
pediatrics 
5a 
 
Vanderhoof, 1998 Case series 6 Pediatrics with SBBO NA x Relief of SBBO symptoms not 
relieved with abx therapy 
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Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved. 
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm 
James M. Anderson Center for Health Systems Excellence 
x NA x Six patients with SBBO who did not respond to antibiotic therapy and 
required additional medical or surgical interventions 
x Metronidazole may be used against facultative anaerobes with widest 
popularity as well as Bactrim, aminoglycosides such as Gent, extended 
spectrum PCN and cephalosporins 
5a 
 
Youssef, 2012 Expert opinion NA Pediatrics with SBBO and short bowel 
syndrome 
NA x Scientific and clinical climate is 
ripe for more information 
about molecular 
characterization of the 
microbiome of short bowel 
syndrome patients, so that 
antimicrobials can be tailored  
x NA x In Pediatric Intestinal Rehab Programs, it is commonplace to empirically 
treat patient with short bowel syndrome and classic symptoms of SBBO 
or an anatomic predisposition to SBBO with an enteral decontaminant 
x Antimicrobials are often cycled for 1-2 weeks each month 
x Other management considerations include glutamine and probiotics, 
but the risks/benefits remain unclear 
x Treatment of SBBO in pediatric patients with short bowel syndrome is 
largely unscientific and typically empiric 
5a 
Dehmer, 2011 Expert opinion NA Pediatrics with SBBO and short bowel 
syndrome 
NA x  
x NA x Suggested antibiotics: metronidazole, sulfamethoxazole/trimethoprim, 
aminoglycoside, amoxicillin-clavulanic acid, and rifiaximin 
5a 
Vanderhoof, 2003 Expert opinion NA Pediatrics with SBBO NA x Treatment aimed to decrease 
bacterial replication with 
antibiotics or surgically correct 
anatomic anomaly 
x NA x Suggested antibiotics: metronidazole, sulfamethoxazole/trimethoprim, 
gentamycin, extended spectrum penicillin, tetracycline 
x Suggested non-antibiotic approaches: polyethylene glycol 
5a 
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Ching 2007 √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Cole 2007 √ √ √ √ √ √ √ √ √ √
Cole 2013 √ √ √ √ √ √ √ √
Dehmer 2011 √ √ √ √ √ √
DiBaise 2006 √ √ √ √ √ √ √
Malik 2011 √ √ √ √ √ √ √ √
Quigley 2006 √ √ √ √ √ √ √ √ √ √ √
Reed 2014 √ √ √ √ √ √ √ √ √ √ √ √
Sentongo 2008 √ √ √ √ √ √
Shah 2013 √ √ √ √
Sieczkowska 2016 √ √ √ √ √ √ √ √
Vanderhoof 1998 √ √ √ √ √ √ √ √ √ √
Vanderhoof 2003 √ √ √ √ √ √ √ √ √
Youssef 2012 √ √ √
Totals 1 1 1 1 8 4 7 2 2 1 4 6 11 6 1 3 3 9 5 1 9 2 5 4 1 11 3 6
Antibiotic	treatment	options
Non-antibiotic	
treatment	options
Pediatric Literature Synthesis Table
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EBDM Evidence Summary Table 
CHARACTERISTICS |  RESULTS  |  CONCLUSIONS  |  EVIDENCE LEVELS 
 
Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved. 
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm 
James M. Anderson Center for Health Systems Excellence 
TITLE, IF APPLICABLE OR IF MULTIPLE TABLES 
Study Citation 
Study Type N 
Sample Size 
Population 
(Setting, Patients) 
Intervention / Comparison Groups Outcomes 
Significant Results 
Including estimates with associated precision (e.g., Odds Ratios or NNT with Confidence Intervals) 
Conclusions  
Including Limitations, Gaps, Applicability, or other Notes 
Evidence 
Level 
DiStefano, 2005 CCT 21 Adults with SBBO Rifaximin followed by Flagyl; Rifaximin course x 2; Flagyl 
course x 2 
x Flagyl is more effective than 
Rifaximin in the treatment of 
SBBO 
x Both drugs reduced H2 breath test excretion values, but significantly lower after 
Flagyl; both drugs induced a significant improvement in symptoms severity but the 
reduction was significantly higher after Flagyl 
x Both drugs improved symptoms, the effect was significantly better with 
Flagyl 
3a 
Lauritano, 2005 Prospective 
cohort 
90 Adults with SBBO Rifaximin 600 mg/d vs 800 mg/d vs 1200 mg/d x Higher dose of rifaximin had 
greater normalization of 
glucose breath test 
x Glucose breath test normalization was significantly higher in the 1200 mg/d group 
(60%) with respect to group 1 (17%; P <0.001) and group 2 (27%, P<0.01) 
x Higher doses was effective without increasing side effects 3b 
Attar, 1999 Longitudinal 10 Adults with SBBO-related diarrhea Five 7-day treatment periods: untreated (control), placebo, 
then in random and blinded fashion, norfloxacin (800 
mg/d), amoxicillin-clavulanic acid (1500 mg/d), and 
Saccharomyces boulardii (1500 mg/d) 
x Norfloxacin and amox-clav acid 
are effective in the treatment 
of SBBO 
x Daily stool frequency similar during control and placebo; Norfloxacin and amox-clav 
acid led to a significant reduction in daily stool frequency (P<0.01 vs placebo). 
Breath-expired H2 volume decreased with norfloxacin and amox-clav 
x Norfloxacin and amox-clav acid reduce the number of stools and 
abnormal bacterial metabolic activity in SBBO-related diarrhea 
4a 
Bohm, 2013 Expert opinion N/A Adults with SBBO N/A x Management includes: 
identifying and correcting 
underlying causes, addressing 
nutrition deficiencies, 
implementing diet 
modification, and using abx   
x N/A x Amox-clav acid and norfloxacin have been shown to reduce stool 
frequency; Flagyl and Cipro have been effective for SBBO with Crohn’s. 
Rifaximin is better at reducing breath test but not better than placebo 
for reducing symptoms associated with celiac disease and ab pain in 
children 
5b 
Lauritano, 2009 Prospective 
randomized trial 
135 Adults with SBBO (IBS or other functional 
disorder) 
Patients were randomized to two 7-day treatment groups: 
rifaximin 1200 mg/d and metronidazole 750 mg/d 
x Rifaximin showed a higher 
SBBO decontamination rate 
than metronidazole 
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Copyright © 2005–2011 Cincinnati Children's Hospital Medical Center; all rights reserved. 
EBDM Tools & Resources – http://groups/ce/NewEBC/ToolsResources.htm 
James M. Anderson Center for Health Systems Excellence 
x Glucose breath tests normalization rate was significantly higher in the rifaximin 
group compared to the metronidazole group (63.4% vs 43.7%, p<0.05, OR 1.50, 95% 
CI 1.14-4.38) 
x The overall prevalence of adverse events was significantly lower in 
rifaximin group compared to metronidazole group. Rifaximin had better 
decontamination rates 
3a 
Parrish, 2015 Expert opinion N/A Adults with SBBO and short bowel syndrome N/A x Excessive bacteria in the small 
bowel can induce 
inflammatory and atrophic 
changes in the gut impairing 
absorption, deconjugate bile 
acids resulting in fat 
maldigestion, consume vitamin 
B12 leading to deficiency, 
cause gas-related symptoms, 
and aggravate diarrhea 
x N/A x Antimicrobial treatment is often empirically prescribed with success 
judged on improvements in symptoms, reduction in stool output and/or 
weight gain.  
x Amoxcillin-clavulanate 500 mg 2-3 times daily 
x Cephalexin 250 mg 2 times daily 
x Ciprofloxacin 500 mg 2 times daily 
x Doxycycline 100 mg 2 times daily 
x Metronidazole 250 mg 3 times daily 
x Neomycin 500 mg 2 times daily 
x Norfloxacin 400 mg 2 times daily 
x Rifaximin 250-500 mg 2-3 times daily 
x Tetracycline 250-500 mg 4 times daily 
x Trimethoprim-Sulfamethoxazole 1 double-strength tablet 2 times daily 
5a 
     x  
x  x   
     x  
x  x   
     x  
x  x   
     x  
x  x   
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LEGEND 
Let Evidence Guide Every New Decision 
Judging the Strength of a Recommendation 
 
 
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.                     June 11, 2012 
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library | 
Occupational Therapy & Physical Therapy | Hospital Medicine                www.cincinnatichildrens.org/evidence 
Project Title: The use of antibiotic therapy to treat small bowel bacterial 
overgrowth in the pediatric population with short bowel syndrome 
Recommendation 1: Identify risk factors for SBBO 
Date: 5/5/2017 
In determining the strength of a recommendation, the development group makes a considered judgment. 
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience, 
and other dimensions.  The development group will consider what the relative weight each dimension listed below 
contributes when determining the strength of a recommendation. 
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates support for a 
stronger recommendation, complete one of the sentences below to judge the strength of this recommendation. 
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
x  It is strongly recommended that … risk factors for 
SBBO be identified  
 It is recommended that… 
 There is insufficient evidence and a lack of 
consensus to make a recommendation on… 
 
 
Dimensions 
1. Grade of the Body of Evidence High grade evidence  Moderate grade 
evidence 
x Low grade evidence 
2. Safety / Harm x Has minimal adverse 
effects 
 Has moderate adverse 
effects 
 Has serious adverse 
effects 
3. Benefit to target population 
 (e.g., health benefit to patient) 
x Has significant benefit  Has moderate benefit  Has minimal benefit 
4. Burden on population to adhere to 
recommendation 
(e.g., cost, hassle, discomfort, pain, 
motivation, ability to adhere, time) 
x Low burden of 
adherence 
 Unable to determine 
burden of adherence 
 High burden of 
adherence 
5. Cost-effectiveness to healthcare 
system  
(e.g., balance of cost/savings of 
resources, staff time, supplies based 
on published studies/onsite analysis) 
x Cost-effective to 
healthcare system 
 Inconclusive economic 
effects 
 Not cost-effective to 
healthcare system 
6. Directness 
(the extent to which the body of 
evidence directly answers the clinical 
question [population/problem, 
intervention, comparison, outcome]) 
x Evidence directly 
relates to 
recommendation for 
this target population. 
 There is some concern 
about the directness of 
evidence as it relates to 
the recommendation for 
this target population. 
 Evidence only 
indirectly relates to 
recommendation for 
this target population. 
7. Impact on morbidity, mortality, or 
quality of life 
x High impact on 
morbidity, mortality, or 
quality of life 
 Medium impact on 
morbidity, mortality, or 
quality of life 
 Low impact on 
morbidity, mortality, or 
quality of life 
 
Some of the concepts for this development based on: 
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians 
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6, 
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005. 
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Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.                     June 11, 2012 
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library | 
Occupational Therapy & Physical Therapy | Hospital Medicine                www.cincinnatichildrens.org/evidence 
Project Title: The use of antibiotic therapy to treat small bowel bacterial 
overgrowth in the pediatric population with short bowel syndrome 
Recommendation 1: Identify signs and symptoms of SBBO 
Date: 5/5/2017 
In determining the strength of a recommendation, the development group makes a considered judgment. 
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience, 
and other dimensions.  The development group will consider what the relative weight each dimension listed below 
contributes when determining the strength of a recommendation. 
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates support for a 
stronger recommendation, complete one of the sentences below to judge the strength of this recommendation. 
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
x  It is strongly recommended that … signs and 
symptoms of SBBO be identified  
 It is recommended that… 
 There is insufficient evidence and a lack of 
consensus to make a recommendation on… 
 
 
Dimensions 
1. Grade of the Body of Evidence High grade evidence  Moderate grade 
evidence 
x Low grade evidence 
2. Safety / Harm x Has minimal adverse 
effects 
 Has moderate adverse 
effects 
 Has serious adverse 
effects 
3. Benefit to target population 
 (e.g., health benefit to patient) 
x Has significant benefit  Has moderate benefit  Has minimal benefit 
4. Burden on population to adhere to 
recommendation 
(e.g., cost, hassle, discomfort, pain, 
motivation, ability to adhere, time) 
x Low burden of 
adherence 
 Unable to determine 
burden of adherence 
 High burden of 
adherence 
5. Cost-effectiveness to healthcare 
system  
(e.g., balance of cost/savings of 
resources, staff time, supplies based 
on published studies/onsite analysis) 
x Cost-effective to 
healthcare system 
 Inconclusive economic 
effects 
 Not cost-effective to 
healthcare system 
6. Directness 
(the extent to which the body of 
evidence directly answers the clinical 
question [population/problem, 
intervention, comparison, outcome]) 
x Evidence directly 
relates to 
recommendation for 
this target population. 
 There is some concern 
about the directness of 
evidence as it relates to 
the recommendation for 
this target population. 
 Evidence only 
indirectly relates to 
recommendation for 
this target population. 
7. Impact on morbidity, mortality, or 
quality of life 
x High impact on 
morbidity, mortality, or 
quality of life 
 Medium impact on 
morbidity, mortality, or 
quality of life 
 Low impact on 
morbidity, mortality, or 
quality of life 
 
Some of the concepts for this development based on: 
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians 
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6, 
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005. 
	 	
	
93 
 
 
 
 
LEGEND 
Let Evidence Guide Every New Decision 
Judging the Strength of a Recommendation 
 
 
Copyright © 2005-2012 Cincinnati Children's Hospital Medical Center; all rights reserved.                     June 11, 2012 
CCHMC Evidence Collaboration: James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library | 
Occupational Therapy & Physical Therapy | Hospital Medicine                www.cincinnatichildrens.org/evidence 
Project Title: The use of antibiotic therapy to treat small bowel bacterial 
overgrowth in the pediatric population with short bowel syndrome 
Recommendation 1: Identify antibiotics for the treatment of SBBO 
Date: 5/5/2017 
In determining the strength of a recommendation, the development group makes a considered judgment. 
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience, 
and other dimensions.  The development group will consider what the relative weight each dimension listed below 
contributes when determining the strength of a recommendation. 
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates support for a 
stronger recommendation, complete one of the sentences below to judge the strength of this recommendation. 
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
x  It is strongly recommended that … antibiotics for 
the treatment of SBBO be identified  
 It is recommended that… 
 There is insufficient evidence and a lack of 
consensus to make a recommendation on… 
 
 
Dimensions 
1. Grade of the Body of Evidence High grade evidence x Moderate grade 
evidence 
Low grade evidence 
2. Safety / Harm x Has minimal adverse 
effects 
 Has moderate adverse 
effects 
 Has serious adverse 
effects 
3. Benefit to target population 
 (e.g., health benefit to patient) 
x Has significant benefit  Has moderate benefit  Has minimal benefit 
4. Burden on population to adhere to 
recommendation 
(e.g., cost, hassle, discomfort, pain, 
motivation, ability to adhere, time) 
Low burden of 
adherence 
x Unable to determine 
burden of adherence 
 High burden of 
adherence 
5. Cost-effectiveness to healthcare 
system  
(e.g., balance of cost/savings of 
resources, staff time, supplies based 
on published studies/onsite analysis) 
x Cost-effective to 
healthcare system 
 Inconclusive economic 
effects 
 Not cost-effective to 
healthcare system 
6. Directness 
(the extent to which the body of 
evidence directly answers the clinical 
question [population/problem, 
intervention, comparison, outcome]) 
x Evidence directly 
relates to 
recommendation for 
this target population. 
 There is some concern 
about the directness of 
evidence as it relates to 
the recommendation for 
this target population. 
 Evidence only 
indirectly relates to 
recommendation for 
this target population. 
7. Impact on morbidity, mortality, or 
quality of life 
x High impact on 
morbidity, mortality, or 
quality of life 
 Medium impact on 
morbidity, mortality, or 
quality of life 
 Low impact on 
morbidity, mortality, or 
quality of life 
 
Some of the concepts for this development based on: 
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians 
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6, 
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005. 
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Appendix K 
Agency Approval form 
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Appendix L 
IRB Determination Cincinnati Children’s Hospital Medical Center 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	
	
96 
Appendix M 
IRB Determination Wright State University 
 
If you have questions regarding the review and approval of this study, please contact Jodi 
Blacklidge at jodi.blacklidge@wright.edu or 937-775-3974. 
Thank you, 
The Wright State University IRB 
OHRP #IRB00000034 
 
Office of Research and Sponsored Programs
201J University Hall
3640 Col. Glenn Hwy.
Dayton, OH 45435-0001
(937) 775-2425
(937) 775-3781 (FAX)
e-mail: rsp@wright.edu
Notification date: September 15, 2017
PI: Christina Heinzman,
Doctor of Nursing Practice
program
IRB #: 06124
WSU IRB INITIAL APPROVAL – EXPEDITED REVIEW
Study expiration date:
September 14, 2018
Study approval date:
September 15, 2017
Expedited via category: 5
Title:
The role of antibiotic therapy in the treatment of small bowel bacterial
overgrowth in pediatric patients with short bowel syndrome
Approval
The Wright State University (WSU) IRB reviewed and approved the above study via
expedited review for 12 months at other location(s): Cincinnati Children's Hospital Medical
Center.
Waivers
The WSU IRB granted the following waivers for this study: Waiver of authorization and
consent.
Required Findings
The WSU IRB also found that this study met the following criteria for use of vulnerable
populations: Children 45 CFR 46.404.
Investigator Responsibilities
If this is a VA study, you must receive an additional approval letter from the VA R&D
Committee prior to initiating the study.
You must obtain IRB approval of any changes to this study prior to implementation.
You must receive continuing review of this study prior to the expiration date above.
If the study approval expires, you must not accrue additional subjects, collect data
and/or review medical records until proper renewal is obtained.
You must report any unanticipated problems or other problems/events in accordance
with WSU IRB policy.
file:///Users/connorbrewer/Downloads/Initial approval-1.htm
1 of 2 5/12/18, 11:42 AM
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Appendix N 
Data Collection Tool 
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Appendix O 
Risk Factors & Signs and Symptoms 
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Attar 1999 √ √
Bohm 2013 √ √ √ √ √ √ √ √ √ √ √
Ching 2007 √ √ √ √ √ √ √ √ √
Cole 2007 √ √ √ √ √ √ √ √ √ √
Collins 2011 √ √ √ √ √ √
DiBaise 2006 √ √ √ √ √ √ √ √ √ √ √
DiStefano 2005 √ √ √ √ √ √ √ √
Gutierrez 2012 √ √
Lauritano 2005
Lauritano 2009 √ √ √ √ √
Malik 2011 √ √ √ √ √ √ √ √ √
Quigley 2006 √ √ √ √ √
Reed 2014 √ √ √ √ √ √ √ √ √
Parrish 2015 √ √ √ √ √ √ √ √
Vanderhoof 2003 √ √ √ √ √ √ √
Dehmer 2011 √ √ √
Sieczkowski 2016 √ √ √ √ √ √ √ √ √
Youssef 2012 √ √ √ √ √ √ √
Sentongo 2008 √ √ √ √ √ √ √
Cole 2013 √ √ √ √ √
RISK	
FACTORS SIGNS	&	SYMPTOMS
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Appendix P 
BESt Document Draft 
June 5, 2018 
Antibiotic therapy for small bowel bacterial overgrowth in pediatric 
patients with short bowel syndrome/intestinal failure 
INTRODUCTION / BACKGROUND 
Patients with short bowel syndrome/intestinal failure are at risk for the development of small bowel bacterial 
overgrowth, a serious consequence caused by overgrowth of bacteria in the small bowel resulting in symptoms 
of abdominal pain, abdominal distention, feeding intolerance, malabsorption, weight loss and increased risk of 
metabolic acidosis.  Clinical studies assessing the role of antibiotic therapy in the pediatric population are nearly 
non-existent forcing clinicians to rely on adult literature for guidance.  Diagnostic testing methods are often 
invasive and difficult to perform in pediatric patients leaving clinicians to diagnosis this condition based on 
symptomology.  Treatment is often prescribed based on clinical experience and published expert opinion.  
Inconsistency in the diagnosis and medical treatment of small bowel bacteria overgrowth is problematic at 
CCHMC. A one-year retrospective chart review of pediatric patients admitted to the Gastroenterology/Lumen 
service at Cincinnati Children’s Hospital Medical Center between 5/1/2016-5/1/2017 was conducted.  Final 
analysis of the data revealed inconsistency in antibiotic prescribing methods and in many cases overprescribing. 
A best evidence statement (BESt) has been drafted for publication throughout the institution with the intent to 
standardize antibiotic prescribing practices for this population.  
Definitions for terms marked with * and Abbreviations may be found in an Abbreviations and Definitions section below. 
CLINICAL QUESTION 
 
P (Population/Problem) In pediatric patients with short bowel syndrome and signs/symptoms of SBBO 
I (Intervention) Does treatment with antibiotic therapy 
C (Comparison) Compared to no treatment 
O (Outcome) Affect the symptoms of abdominal distention, vomiting and increased stool output? 
 
TARGET POPULATION FOR THE RECOMMENDATION 
Inclusion Criteria 
The population of interest includes pediatric patients with a diagnosis of short bowel syndrome or intestinal 
failure secondary to omphalocele, gastroschisis, duodenal atresia, jejunal atresia, ileal atresia, necrotizing 
enterocolitis, malrotation with volvulus, Hirschsprung’s disease, presence of an ostomy, or traumatic bowel 
injury who have EITHER “symptoms” of small bowel bacterial overgrowth (SBBO) including nausea/vomiting, 
dehydration, abdominal pain, abdominal distention/bloating/gas, diarrhea/steatorrhea, hematochezia, weight 
loss, malabsorption or metabolic acidosis OR other “risk factors” including dysmotility, chronic pseudo-
obstruction, megacystis megacolon intestinal hypoperistalsis syndrome, radiation enteropathy, H pylori, proton 
pump inhibitor use, hypochlorhydria, and total or subtotal gastrectomy, immunodeficiency, malnutrition, 
parenteral nutrition dependence, or chronic pancreatitis.  
Exclusion Criteria 
Anyone who does not meet the above criteria is excluded from this recommendation.  
Best Evidence Statement – BESt 
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TARGET USERS FOR THE RECOMMENDATIONS 
Target users include, clinical providers including but are not limited to physicians, residents, and nurse 
practitioners.  
EVIDENCE–BASED CARE RECOMMENDATION 
Recommendation #1: It is strongly recommended that providers properly identify risk 
factors for SBBO.   
Dimensions of Judging the Recommendation Strength for providers 
properly identify risk factors for SBBO.  
1. Safety / Harm   (Side Effects and Risks)  Minimal   Moderate / Neutral  Serious  
2. Health benefit to patient  Significant  Moderate / Neutral   Minimal  
3. Burden on population to adhere to recommendation  Low   Unable to determine   High 
4. Cost-effectiveness to healthcare system  Cost-effective  Inconclusive  Not cost-effective 
5. Directness of the evidence for this target population  Directly relates  Some concern of directness  Indirectly relates  
6. Impact on quality of life, morbidity, or mortality  Positive  Moderate / Neutral  Negative 
7. Grade of the Body of Evidence 
(See Evidence Table below; *GNA – Grade Not Assignable) 
 High 
 
 Moderate 
 
 Low 
 
 Very Low 
 
 GNA* 
 
Overall Strength of the Recommendation:  Strong  Moderate  Weak       Consensus Only 
Given the dimensions above for each recommendation and that more answers to the left of the scales indicate support for 
a stronger recommendation, the recommendation statements reflect the strength of each recommendation as judged by 
the development group. 
(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
Discussion/Synthesis of the Evidence and Dimensions for the Recommendation 
Learning to identify risk factors has the potential for significant benefit to this population in terms of 
morbidity, mortality and quality of life.  The evidence presented to support this recommendation is largely 
based on expert opinion, clinical experience, and literature review, as well as the limited pediatric research 
available (Bohm, Siwiec, & Wo, 2013a; Chan, Parrish, & DiBaise, 2015; Ching, Gura, Modi, & Jaksic, 2007; 
Cole & Ziegler, 2007; Collins & Lin, 2011; Dehmer, Fuller, & Helmrath, 2011; Di Stefano, Miceli, Missanelli, 
Mazzocchi, & Corazza, 2005; DiBaise, Young, & Vanderhoof, 2006; Gutierrez et al., 2012; Lauritano et al., 
2009; Malik, Xie, Wine, & Huynh, 2011; Quigley & Quera, 2006; Reed, 2014; Vanderhoof, Young, & 
Thompson, 2003).  Knowing the risk factors for SBBO, has the potential to minimize overprescribing of 
unnecessary antibiotics.  Overprescribing leads to increased healthcare expenses while failure to comply with 
antibiotic stewardship increases risk of multi-resistant organisms.  
__________ 
Recommendation #2: It is strongly recommended that providers receive educational training in the 
identification of the signs and symptoms of SBBO.  
Dimensions of Judging the Recommendation Strength that providers receive educational 
training in the identification of the signs and symptoms of SBBO 
1. Safety / Harm   (Side Effects and Risks)  Minimal   Moderate / Neutral  Serious  
2. Health benefit to patient  Significant  Moderate / Neutral   Minimal  
3. Burden on population to adhere to recommendation  Low   Unable to determine   High 
4. Cost-effectiveness to healthcare system  Cost-effective  Inconclusive  Not cost-effective 
5. Directness of the evidence for this target population  Directly relates  Some concern of directness  Indirectly relates  
(Arnott, McNeill, & 
Satsangi, 2003) 
Best Evidence Statement – BESt 
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6. Impact on quality of life, morbidity, or mortality  Positive  Moderate / Neutral  Negative 
7. Grade of the Body of Evidence 
(See Evidence Table below; *GNA – Grade Not Assignable) 
 High 
 
 Moderate 
 
 Low 
 
 Very Low 
 
 GNA* 
 
Overall Strength of the Recommendation:  Strong  Moderate  Weak       Consensus Only 
Given the dimensions above for each recommendation and that more answers to the left of the scales indicate support for 
a stronger recommendation, the recommendation statements reflect the strength of each recommendation as judged by 
the development group. 
(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
Discussion/Synthesis of the Evidence and Dimensions for the Recommendation 
Second, it is strongly recommended that providers receive educational training in the identification of the signs 
and symptoms of SBBO (Bohm et al., 2013a; Chan et al., 2015; Ching et al., 2007; Cole & Ziegler, 2007; 
Collins & Lin, 2011; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et al., 2006; Gutierrez et al., 2012; 
Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014; Vanderhoof et al., 2003).  
Identifying the signs and symptoms of SBBO also has the potential to have great impact on the quality of life 
for those affected.  Differentiating the signs and symptoms of SBBO from other etiologies will allow providers 
to more quickly recognize when an antibiotic therapy is indicated and when it is not.  
__________ 
Recommendation #3:  It is recommended that providers receive educational training in the prescribing of 
preferred antibiotics and doses for the treatment of SBBO.  
Dimensions of Judging the Recommendation Strength that providers receive educational 
training in the identification of the signs and symptoms of SBBO 
1. Safety / Harm   (Side Effects and Risks)  Minimal   Moderate / Neutral  Serious  
2. Health benefit to patient  Significant  Moderate / Neutral   Minimal  
3. Burden on population to adhere to recommendation  Low   Unable to determine   High 
4. Cost-effectiveness to healthcare system  Cost-effective  Inconclusive  Not cost-effective 
5. Directness of the evidence for this target population  Directly relates  Some concern of directness  Indirectly relates  
6. Impact on quality of life, morbidity, or mortality  Positive  Moderate / Neutral  Negative 
7. Grade of the Body of Evidence 
(See Evidence Table below; *GNA – Grade Not Assignable) 
 High 
 
 Moderate 
 
 Low 
 
 Very Low 
 
 GNA* 
 
Overall Strength of the Recommendation:  Strong  Moderate  Weak       Consensus Only 
Given the dimensions above for each recommendation and that more answers to the left of the scales indicate support for 
a stronger recommendation, the recommendation statements reflect the strength of each recommendation as judged by 
the development group. 
(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
Discussion/Synthesis of the Evidence and Dimensions for the Recommendation 
Finally, it is recommended that providers receive educational training in the identification of suitable antibiotics 
and doses for the treatment of SBBO (Attar et al., 1999; Bohm et al., 2013a; Chan et al., 2015; Ching et al., 
2007; Cole & Kocoshis, 2013; Cole & Ziegler, 2007; Dehmer et al., 2011; Di Stefano et al., 2005; DiBaise et 
al., 2006; Lauritano et al., 2005; Lauritano et al., 2009; Malik et al., 2011; Quigley & Quera, 2006; Reed, 2014; 
Sentongo, 2008; Shah, Day, Somsouk, & Sewell, 2013; Sieczkowska, Landowski, Kaminska, & Lifschitz, 
2016; Vanderhoof, Young, Murray, & Kaufman, 1998; Vanderhoof et al., 2003; Youssef, Mezoff, Carter, & 
Cole, 2012).  This recommendation was given a strong recommendation.  Based on the multitude of clinical 
experiences, expert opinion, and the limited number of interventional studies available, there is a support for a 
handful of specific antibiotics which have been shown to be effective in minimizing symptoms. Experts from 
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the Division of Gastroenterology, Hepatology, & Nutrition and Infectious Diseases have reviewed the patient 
population, literature and current prescribing practices. It is recommended that a provider choose from 
metronidazole, nitazoxanide, rifaximin, or sulfamethoxazole/trimethoprim with doses/frequency described 
below: 
- Metronidazole *** mg/kg every *** hours for *** days 
- Nitazoxanide *** mg/kg every *** hours for *** days 
- Rifaximin *** mg/kg every *** hours for *** days 
- Sulfamethoxazole/trimethoprim *** mg/kg every *** hours for *** days 
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Algorithm for … (if applicable) 
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ABBREVIATIONS AND DEFINITIONS 
Abbreviations  
SBBO – small bowel bacterial overgrowth 
Definitions 
Term(s) and definition(s) 
 
 
IMPLEMENTATION 
Applicability & Feasibility Issues 
Text 
Describe items that may positively or negatively impact the successful implementation of this recommendation, such as:  
• Define potential facilitators and barriers within the practice setting that may help or hinder the implementation 
• Facilitators   (e.g., leadership support, strong evidence, staff education support) 
• Barriers   (e.g., systems not in place, resources not available, baseline data not available, not currently an organizational priority, unfamiliarity 
with the quality improvement process) 
• Determine potential resource needs   (e.g., cost, equipment availability, appropriate staff availability)  
Relevant CCHMC Tools 
Text 
Identify tools or processes which need to be developed, adapted, or revised for incorporation of the recommendation into 
practice (e.g., clinical pathways, order sets, EPIC/EMR, family education materials, Knowing Notes, Health Topics, or None were found). 
Outcome Measures 
Text 
This section briefly describes the desired outcomes resulting from implementation of the recommendation, how the outcomes are 
measured, and how success is identified. 
Outcome measures may include (but are not limited to) patient satisfaction, health status, illness, injury, readmission, hospitalization, 
length of stay (LOS), morbidity, mortality, incidence, prevalence, etc. Consider outcomes cited in the evidence for the recommendation. 
Include the rationale for measuring these outcomes. How will you know your recommendations have improved the outcome? 
Consider work flow when choosing outcome measures to not over-burden clinicians, families, and staff. 
(If outcome assessment requires additional monitoring beyond what is already captured in normal work processes, consider using tools that have 
already been validated to monitor those outcomes and processes, if available.) 
Process Measures 
Text 
This section briefly describes the related processes necessary to obtain the outcomes above.  
Process measures evaluate the way care is provided. These may include technical (e.g., procedures, therapies, wait time, cost, LOS) or 
interpersonal (e.g., communication, compassion) processes. Consider processes cited in the evidence for the recommendation. Include the 
rationale for measuring these processes. How will you know your recommendations have improved the process? 
Consider work flow when choosing process measures to not over-burden clinicians, families, and staff. 
(If process assessment requires additional monitoring beyond what is already captured in normal work processes, consider using tools that have already 
been validated to monitor those outcomes and processes, if available.)  
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INCLUSION CRITERIA, EVIDENCE SEARCH STRATEGY, & SEARCH RESULTS 
Criteria for considering studies for this review 
Types of Studies Study designs which were considered for inclusion in the systematic review 
Types of Participants Patients/Population(s) which were considered for inclusion in the systematic review 
(What populations were applicable to this review? For example, only pediatric studies were 
planned for inclusion.) 
Types of Interventions Interventions and Comparisons which were considered for inclusion in the systematic review 
Types of Outcomes Outcomes which were considered for inclusion in the systematic review 
Exclusion Criteria, if any Additional criteria for exclusion that go beyond simply the opposite of the inclusion criteria 
Search Strategy 
Search Methods 
To select evidence for critical appraisal by the group for this BESt, the databases below were searched using search terms, limits, 
filters, and date parameters to generate an unrefined, “combined evidence” database.  This search strategy focused on answering the 
clinical questions addressed in this document and employing a combination of Boolean searching on human-indexed thesaurus terms 
(e.g., MeSH) as well as “natural language” searching on words in the title, abstract, and indexing terms. 
Search Databases Search Terms 
Limits, Filters, &  
Search Date 
Parameters 
Date of 
Most 
Recent 
Search 
 MedLine  
via PubMed or 
Ovid 
 CINAHL 
 Cochrane 
Database for 
Systematic 
Reviews 
 PsycInfo 
 Other:  
Keyword(s), subject, 
headings, MeSH terms 
Database Limits 
applied 
   
small bowel bacterial 
overgrowth, small intestine 
bacterial overgrowth, SBBO, 
SIBO, blind loop syndrome, 
antibiotic, prophylactic 
antibiotic, antibacterial 
agents, or anti-infective 
agents 
Cochrane 
Database 
for 
Systematic 
Reviews 
2006 to 
present, 
English 
language 
"Intestine, 
Small/microbiology"[MAJR] 
AND "humans"[MeSH 
Terms]) AND ("Anti-
Bacterial Agents "[MeSH] 
AND "humans"[MeSH 
Terms]) AND 
"humans"[MeSH Terms] 
AND 
PubMed 2006 to 
present, 
English 
language 
Small bowel bacterial 
overgrowth AND antibiotics 
CINAHL 2006 to 
present, 
English 
language 
 
Publication Dates or 
Search Dates 
• 2006 to present 
1/1/2018 
 English Language 
 Pediatric Evidence 
Only: 
• X 
 Other Limits or 
Filters: 
• X 
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Search Results 
The citations were reduced by eliminating duplicates, review articles, non-English articles, and adult articles (e.g., limits/filters above).  
The resulting abstracts and full text articles were reviewed by a methodologist to eliminate low quality and irrelevant citations or articles.  
During the course of the BESt development, additional articles were identified from subsequent refining searches for evidence, clinical 
questions added to the guideline and subjected to the search process, and hand searching of reference lists.  The dates of the most 
recent searches are provided above. 
The initial search for evidence identified 26 articles. 
13 articles met the inclusion criteria above. 
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David Haslam, Infectious Disease physician, Cincinnati Children’s Hospital Medical Center 
Josh Courter, Infectious Disease pharmacist, Cincinnati Children’s Hospital Medical Center 
Other Evidence-Based Care Recommendation Development Support 
Content Reviewers: 
Support/Consultants: 
Methodologist: 
Conflicts of Interest were declared for each team member and: 
  No financial or intellectual conflicts of interest were found. 
 No external funding was received for development of this recommendation. 
 The following conflicts of interest were disclosed: 
Firstname Lastname – State found conflicts. 
Firstname Lastname – State found conflicts. 
Firstname Lastname – State found conflicts. 
 
Conflict of interest declarations information is maintained in Cincinnati Children’s ePAS (electronic Protocol Administration System). 
 
FUTURE RESEARCH AGENDA 
  
Best Evidence Statement – BESt 
	
	
Copyright	©	2011–2018	Cincinnati	Children's	Hospital	Medical	Center;	all	rights	reserved.																					February	26,	2018	 	
CCHMC	Evidence	Collaboration:	 James	M.	Anderson	Center	for	Health	Systems	Excellence	|	Center	for	Professional	Excellence	|	
Edward	L.	Pratt	Research	Library	|	Occupational	Therapy	&	Physical	Therapy	|	Hospital	Medicine	 www.cincinnatichildrens.org/evidence	
107 
LEGEND EVIDENCE EVALUATION SYSTEM   (LET EVIDENCE GUIDE EVERY NEW DECISION) 
Full tables of the LEGEND evidence evaluation system are available in separate documents: 
• Table of Evidence Levels of Individual Studies by Domain, Study Design, & Quality (abbreviated table below) 
• Grading a Body of Evidence to Answer a Clinical Question 
• Judging the Strength of a Recommendation 
 
Table of Evidence Levels (see link above for full table): 
       †a = good quality study; b = lesser quality study 
 
Table of Grade for the Body of Evidence (see link above for full table): 
 
Table of Language and Definitions for Recommendation Strength (see link above for full table): 
Language for Strength Definition 
It is strongly recommended that… 
It is strongly recommended that… not… 
When the dimensions for judging the strength of the evidence are applied, 
there is high support that benefits clearly outweigh risks and burdens. 
(or visa-versa for negative recommendations) 
It is recommended that… 
It is recommended that… not… 
When the dimensions for judging the strength of the evidence are applied, 
there is moderate support that benefits are closely balanced with risks and 
burdens. 
It is suggested that… 
It is suggested that… not… 
When the dimensions for judging the strength of the evidence are applied, 
there is weak support that benefits are closely balanced with risks and burdens. 
There is insufficient evidence to make a recommendation… 
 
 
 
 
 
EVIDENCE-BASED CLINICAL CARE RECOMMENDATION DEVELOPMENT PROCESS 
The process by which these recommendation statements were developed is documented in the BESt Development Process Manual; 
relevant development materials are kept electronically. The recommendations contained in this BESt were formulated by a 
multidisciplinary working group, which performed a systematic search and critical appraisal of the literature using LEGEND (see section 
above). The BESt has been reviewed and approved by clinical experts not involved in the development process. 
Recommendations have been formulated by a consensus process directed by best evidence, patient and family preference, and clinical 
expertise.  During formulation of these recommendations, the team members have remained cognizant of controversies and 
disagreements over the management of these patients.  They have tried to resolve controversial issues by consensus where possible 
and, when not possible, to offer optional approaches to care in the form of information that includes best supporting evidence of efficacy 
for alternative choices. 
Review Process 
This Best Evidence Statement has been reviewed against quality criteria by two independent reviewers from the CCHMC Evidence 
Collaboration. 
Quality Level Definition 
1a† or 1b† Systematic review, meta-analysis, or meta-synthesis of multiple studies 
2a or 2b Best study design for domain 
3a or 3b Fair study design for domain 
4a or 4b Weak study design for domain 
5a or 5b General review, expert opinion, case report, consensus report, or guideline 
5 Local Consensus 
Grade Definition 
High Good quality, High-level studies  with consistent results 
Moderate Good quality, Lower-level OR Lesser quality, Higher-level studies  with consistent* results 
Low Good or lesser quality, Lower-level with results that may be inconsistent 
Very Low Few Good or Lesser quality, Low-level studies that may have inconsistent results 
Grade Not Assignable Local Consensus 
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If the guideline was not externally appraised using the AGREE II criteria, delete the following sentence, list and percentages. 
The guideline was also externally appraised by three independent reviewers using the AGREE instrument (Appraisal of Guidelines for 
Research and Evaluation) and the results by domain are: 
• Scope and Purpose  XXX% 
• Stakeholder Involvement  XXX% 
• Rigor of Development   XXX% 
• Clarity and Presentation   XXX% 
• Applicability    XXX% 
• Editorial Independence   XXX% 
Revision Process 
The BESt will be removed from the Cincinnati Children’s website, if content has not been revised within five years from the most recent 
publication date.  A revision of the BESt may be initiated at any point that evidence indicates a critical change is needed. 
If this is the initial development of the BESt, delete the following paragraph.  If this is a revision, please include: 
The most recent details for the search strategy, results, and review are documented in this BESt.  Details of previous review strategies 
are not documented.  However, all previous citations and content were reviewed for appropriateness to this revision.  Experience with 
the implementation and monitoring of earlier publications of this BESt have provided learnings, which have also been incorporated into 
this revision.  
Review History 
Date Event Outcome 
 Original Publication New BESt developed and published 
 
Permission to Use the BESt 
Copies of this Best Evidence Statement (BESt) and related tools (if applicable, e.g., screening tools, algorithms, etc.) are available 
online and may be distributed by any organization for the global purpose of improving child health outcomes. 
Website address: http://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-care/bests/ 
Examples of approved uses of the BESt include the following: 
• Copies may be provided to anyone involved in the organization’s process for developing and implementing evidence based care; 
• Hyperlinks to the CCHMC website may be  placed on the organization’s website;  
• The BESt may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all 
written or electronic documents; and 
• Copies may be provided to patients and the clinicians who manage their care. 
Notification of CCHMC at EBDMinfo@cchmc.org for any BESt adopted, adapted, implemented, or hyperlinked by the organization is 
appreciated. 
Please cite as: 
Authors, Team Leader, Team Members (Year). Cincinnati Children's Hospital Medical Center: Best Evidence Statement: Title. 
http://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-care/recommendations/default/, BESt number, pages 1-
number, Date. Hyperlink the document. 
For more information 
About Cincinnati Children’s Best Evidence Statements and the development process, contact the Cincinnati Children’s Evidence 
Collaboration at EBDMinfo@cchmc.org. 
Note / Disclaimer 
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a comprehensive 
practice guideline.  These recommendations result from review of literature and practices current at the time of their formulation.  This 
Best Evidence Statement does not preclude using care modalities proven efficacious in studies published subsequent to the current 
revision of this document.  This document is not intended to impose standards of care preventing selective variances from the 
recommendations to meet the specific and unique requirements of individual patients.  Adherence to this Statement is voluntary.  The 
clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding any specific care 
recommendation. 
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Evidence Table for Included Articles   (i.e., articles meeting inclusion criteria; Dimension 1 for each outcome) 
OUTCOME OR TABLE TITLE 
Study Citation 
Study Type N 
Sample Size 
Population 
(Setting, Patients) 
Intervention / Comparison Groups Outcomes Evidence Level 
Significant Results and Conclusions 
Including estimates with associated precision (e.g., Odds Ratios or NNT with Confidence Intervals) as well as Limitations / Risk of Bias, Gaps, Applicability, Consistency, or other Notes 
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**See Appendix F, Summary of 
Pediatric Literature and Appendix 
H, Summary of the Adult Literature 
for Critical Appraisal of the 
included articles.  
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